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Methods and information sources 
In the context of this report, ‘synthetic cannabinoids’ are defined as new psychoactive 
substances that mimic the effects of tetrahydrocannabinol, the major psychoactive substance 
in cannabis. Another common name for this group of substances is ‘synthetic cannabinoid 
receptor agonists’. 
The terms ‘synthetic cannabinoid receptor agonists’, ‘spice’ and ‘synthetic cannabinoid’ were 
searched in Medline, Google Scholar and PubMed. Literature searches used both the 
chemical structure and text queries in online databases; searches were conducted in August 
2019. The publications retrieved were then reviewed for additional relevant references (the 
snowball technique). Searches of the websites of selected medical specialty societies and 
international, national and local government agencies were conducted to identify position 
statements and reports. Search strings were introduced in Google and Google Scholar, and 
the first 100 hits were screened to find additional relevant content. Although the systematic 
searches were conducted in 2018, information from thematic scientific papers and reports 
published in 2019 and 2020 was also included in this report. 
English-language articles were selected from a search of PubMed (National Center for 
Biotechnology Information), Web of Science (Thomson Reuters), Medline and Google 
Scholar. The search terms used were ‘synthetic cannabinoid receptor agonists’, ‘spice’ and 
‘synthetic cannabinoid’. Textual searches were also conducted in popular English-language 
drug forums. 
In addition, exact chemical structure-based searches were done in SciFinder (American 
Chemical Society, Chemical Abstract Service) and Reaxys (Elsevier). As part of the report, 
the individual profiles of selected synthetic cannabinoids were developed. The substances 
were identified by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
based on reports of high availability in Europe and/or reports of serious adverse events. 
Google and specific drug user discussion forums and related websites (such as Bluelight, 
Eve and Rave, and Erowid) were searched for the terms ‘CUMYL-PeGACLONE’, ‘AMB-
FUBINACA’, ‘AB-FUBINACA’, ‘CUMYL-5F-P7AICA’ and ‘5F-MDMB-PICA’, alone or in 
combination with ‘buy’, ‘shop’, ‘research chemical’, ‘synthetic cannabinoid’, ‘dosing’, 
‘poisoning’, ‘kaufen’, ‘räuchermischung’, ‘powder’ or  ‘synthesis’. In addition, colleagues 
within the authors’ scientific networks were contacted to obtain information. 
Searches of open source information, including scientific articles, official reports, grey 
literature, internet drug discussion forums and related websites, were also included. 
Information from the European Union Early Warning System on NPS (EWS), operated by the 
EMCDDA, has been included, as relevant. The EWS is composed of a multiagency and 
multidisciplinary network, which includes the EMCDDA, 29 national early warning systems 
(27 EU Member States, Turkey, and Norway), Europol and its law enforcement networks, the 
European Medicines Agency (EMA), the European Commission and other partners. 
Information from United Nations agencies (the United Nations Office on Drugs and Crime 
and the World Health Organization) as well as from third countries such as Canada, Russia, 
the United Kingdom, and the United States has also been included, as relevant. 




1. Executive summary 
Synthetic cannabinoids are functionally similar to Δ9-tetrahydrocannabinol (Δ9-THC), the 
major psychoactive substance in cannabis. They bind to the same cannabinoid receptors in 
the brain and other organs as THC. They were originally developed by scientists to study the 
body’s endocannabinoid system, as well as to provide insights into disease and to help 
develop new medicines. Around the mid-2000s, they began to appear in Europe in products 
called ‘Spice’ that were sold as ‘legal’ replacements for cannabis. In these products, 
synthetic cannabinoids were mixed with plant material, which could then be smoked as 
cigarettes (‘joints’). In recent years, alongside these smoking mixtures, new products, 
including e-liquids for vaping using electronic cigarettes and paper impregnated with 
synthetic cannabinoids, have been sold on the drug market. Unknown to users, synthetic 
cannabinoids have also been mis-sold or used to adulterate cannabidiol (CBD) and THC e-
liquids, as well as other illicit drugs, such as opioids. Another concerning development is the 
recent adulteration of cannabis products with synthetic cannabinoids in Europe. Typically, 
these adulterated products are low-THC herbal material or resins. In terms of look, smell and 
flavour, these adulterated products would be very difficult to distinguish from ‘genuine’ illicit 
cannabis products and, as a result, users may be unaware that they are using synthetic 
cannabinoids. As synthetic cannabinoids are highly potent substances, people who use 
these products could be at high risk of poisoning. 
Synthetic cannabinoids activate the same cannabinoid receptors in the body as THC. The 
behavioural and physiological effects that have been reported with synthetic cannabinoids 
include relaxation, euphoria, lethargy, depersonalisation, distorted perception of time, 
impaired motor performance, hallucinations, paranoia, confusion, fear, anxiety, dry mouth, 
bloodshot eyes, tachycardia, nausea, and vomiting. 
Despite similarities, however, synthetic cannabinoids can cause more profound intoxication 
than cannabis. Severe poisonings are also more common, and fatalities linked to the 
consumption of these substances have been recorded. There have been case reports of 
serious cardiovascular toxicity (including sudden death), rapid loss of consciousness/coma, 
respiratory depression, seizures and convulsions, hyperemesis, delirium, agitation, 
psychosis, and aggressive and violent behaviour. It appears that, at least in part, these 
effects are due to the high potency of synthetic cannabinoids and the unintentionally high 
doses that users may be exposed to. Firstly, laboratory studies have found that many of the 
cannabinoids sold on the drug market are much more potent than THC and act as full 
agonists at the cannabinoid receptors (THC, in contrast, is a partial agonist). This means 
that, even at very small doses, synthetic cannabinoids can activate the cannabinoid 
receptors much more strongly than THC. Secondly, products containing synthetic 
cannabinoids often contain high doses of the substances. The combination of these two 
factors makes it difficult for users to control the dose that they are exposed to. This can lead 
them to rapidly administer a toxic dose unintentionally. These factors are also responsible for 
the outbreaks of mass poisonings seen with synthetic cannabinoids, which have ranged from 
a handful of people to hundreds, some of whom have died. While many of the outbreaks 
reported so far have been in the United States, they have also occurred in Russia, Canada 




and Europe. Outbreaks due to synthetic cannabinoids being mis-sold or used to adulterate 
cannabis products, as well as other illicit drugs, such as opioids, are increasingly common. 
Such outbreaks can rapidly overwhelm the capacity of emergency responders and hospital 
emergency departments, which is of particular concern given the ongoing COVID-19 
pandemic and the additional burden already placed on healthcare systems. There is no 
approved antidote to poisoning caused by synthetic cannabinoids. The effects on health from 
the chronic use of synthetic cannabinoids are largely unknown; however, regular use has 
been linked to problems such as dependence and withdrawal symptoms. 
Synthetic cannabinoids are used by a range of people, including those who use cannabis, 
those who are regularly subjected to drug-testing procedures (such as prisoners) and people 
who experiment with a range of substances (so called ‘psychonauts’). Increasingly, synthetic 
cannabinoids are also used by some high-risk drug users and other vulnerable groups (such 
as prisoners and people experiencing homelessness), as they have gained a reputation for 
causing profound intoxication, they can be cheaper than other drugs and they are easy to 
smuggle. 
In Europe, synthetic cannabinoids are monitored as new psychoactive substances by the 
European Union Early Warning System. They are the largest group of substances monitored 
by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), with 209 
reported between 1 January 2008 and 31 December 2020. Since 2015, there has been a 
decrease in the number of synthetic cannabinoids appearing for the first time each year on 
the drug market and an overall decrease in seizures of synthetic cannabinoids by law 
enforcement. In part, these changes appear to be related to a disruption in the ‘legal high’ 
trade, which for a period saw new psychoactive substances being sold openly on the high 
street in many countries in Europe. More generally, broader policy responses designed to 
restrict the availability of new psychoactive substances are also likely to have had an effect. 
Despite this, the market in synthetic cannabinoids, once the epitome of the ‘legal highs’ 
phenomenon, continues to evolve and pose a threat to health security. During 2020, signals 
related to two synthetic cannabinoids, MDMB-4en-PINACA and 4F-MDMB-BICA, led the 
EMCDDA to launch initial reports on the substances because of concerns of potential public 
health and social threats to Europe. Both MDMB-4en-PINACA and 4F-MDMB-BICA were 
formally risk assessed by the EMCDDA in December 2020. Based on the risk assessment 
reports, in March 2021 the European Commission proposed that MDMB-4en-PINACA and 
4F-MDMB-BICA be controlled in Europe. Since 2016, a total of seven synthetic cannabinoids 
have been formally risk assessed by the EMCDDA (i.e. MDMB-CHMICA (2016), 5F-MDMB-
PINACA, AB-CHMINACA, ADB-CHMINACA, CUMYL-4CN-BINACA (2017), 4F-MDMB-BICA 
and MDMB-4en-PINACA (2020)). 
Despite measures intended to reduce the availability of synthetic cannabinoids on the drug 
market, data reported to the EMCDDA through the EU Early Warning System show that 
synthetic cannabinoids continue to be widely available across Europe. As noted, the 
relatively low cost, easy availability and high potency of synthetic cannabinoids appear to 
have resulted in increased use among marginalised groups such as people experiencing 
homelessness and prisoners. This development has been associated with an increase in 
reports of serious harms. For example, in prisons, alongside the adverse health effects, the 




market in and use of synthetic cannabinoids has been linked to an increase in aggression, 
violence, bullying and debt. In some cases, this has caused a serious threat to the overall 
safety and security of the prison environment. 
In the future, it can be expected that synthetic cannabinoids with high potency and that are 
easy to synthesise will continue to be introduced into the market. 
The ongoing COVID-19 pandemic and the related response measures may affect the 
existing synthetic cannabinoid drug markets in unpredictable ways. Such effects may extend 
to changes in use and patterns of use of synthetic cannabinoids. Seizures of bulk powders 
by European national customs agencies during the pandemic suggest that synthetic 
cannabinoids continue to be imported into and distributed within Europe. It is possible that, in 
the case of a reduced availability of cannabis and other illicit drugs in Europe, criminal 
groups, as well as drug users, may use a range of replacement substances, including 
synthetic cannabinoids. 
This report provides a technical review of the current body of knowledge regarding synthetic 
cannabinoids that are monitored by the EMCDDA. The aim of this report is to strengthen 
situational awareness of synthetic cannabinoids in Europe and to help stakeholders prepare 
for and respond to public health and social threats caused by such substances. 





2.1. History of the development of synthetic cannabinoids 
The first synthetic analogues of Δ9-tetrahydrocannabinol (Δ9-THC; the major psychoactive 
substance in cannabis) were synthesised by Mechoulam (Mechoulam and Carlini, 1978) 
shortly after the first total synthesis of Δ9-THC was published (Mechoulam and Gaoni, 1965). 
Their chemical structure was similar to the structure of Δ9-THC (e.g. nabilone and A-41988). 
After the identification and cloning of the CB1 and CB2 cannabinoid receptors (Matsuda et al., 
1990; Munro et al., 1993), a variety of chemicals with diverse structures were screened for 
the ability to bind to these receptors. This led to the discovery of several classes of 
substances that could bind to and activate the cannabinoid receptors (Huffman and Padgett, 
2005; Makriyannis and Deng, 2007). Subsequently, a large body of literature on the subject 
emerged, focused on the development of synthetic cannabinoids as medicines. Cannabis 
was recognised as potentially useful for the treatment of conditions such as pain, anorexia, 
wasting syndrome, muscle spasms and glaucoma (Compton et al.,1992; Melvin et al., 1984), 
and new drug candidates were developed, focusing on easy to synthesise synthetic 
cannabinoids with fewer psychotropic side effects than cannabis. Simultaneously, other 
groups were also investigating the structure–activity relationships of this new class of 
substances (Aung et al., 2000; Huffman et al., 2005; Melvin et al., 1993; Wiley et al., 2014). 
2.2. Legitimate uses of synthetic cannabinoids 
Synthetic cannabinoids have been the subject of extensive pharmacological and toxicological 
research. Some were developed as drug candidates. Nabilone (Cesamet®), for example, is 
used as an orally administered medicine for the treatment of nausea and vomiting induced by 
cancer chemotherapy in patients receiving a wide variety of chemotherapy regimens, or to 
treat cachexia under HIV treatment for patients who have failed to respond adequately to 
conventional antiemetic treatments. Owing to its side effects and potential for abuse, which 
are very similar to those of THC, nabilone is not a first-choice therapy. In addition, synthetic 
cannabinoids are widely used in scientific research and in analytical reference material in 
clinical and forensic case work. 
2.3. International control measures 
The following synthetic cannabinoids are included in the list of substances in Schedule II of 
the United Nations Convention on Psychotropic Substances of 1971 (INCB, 2020): 
— AM-2201 (JWH-2201) and JWH-018 (AM-678) (since 2015), 
— 5F-AKB-48 (5F-APINACA), MDMB-CHMICA and XLR-11 (5F-UR-144) (since 2017), 
— AB-CHMINACA, AB-PINACA, 5F-MDMB-PINACA (5F-ADB), AM-2201 carboxylate 
analogue quinolinyl derivative (5F-PB-22) and UR-144 (since 2018), 
— ADB-FUBINACA, AMB-FUBINACA (FUB-AMB), CUMYL-4CN-BINACA and ADB-
CHMINACA (since 2019), 




— AB-FUBINACA, 5F-AMB (5F-AMB-PINACA), 5F-MDMB-PICA and 4F-MDMB-
BINACA (since 2020). 
In 2020, MDMB-4en-PINACA (WHO, 2020a) and CUMYL-PeGACLONE (WHO, 2020b) were 
assessed at the 43rd meeting of the WHO Expert Committee on Drug Dependence and were 
recommended to be included in Schedule II of the 1971 Convention on Psychotropic 
Substances (WHO, 2020c). 




3. Synthetic cannabinoids in Europe 
3.1. Emergence as new psychoactive substances 
A product called ‘Spice’, containing synthetic cannabinoids, appears to have emerged 
around 2004 as a legal alternative to cannabis and started to gain popularity in European 
countries. By 2008, these products were gaining wider popularity and were associated with 
numerous poisonings. Towards the end of 2008, the active substances in these Spice 
products were identified as JWH-018 and CP-47,497-C8, two synthetic cannabinoids 
developed decades ago in the context of research on the endocannabinoid system (Auwärter 
et al., 2009; Uchiyama et al., 2009). These products were found to contain synthetic 
cannabinoids mixed with plant (herbal) material, which could then be smoked as cigarettes 
(‘joints’) (Auwärter et al., 2009; EMCDDA, 2009, 2017; Jack, 2009). Such smoking mixtures 
have been referred to by a variety of names, depending on the country, region, product type, 
brand name and user group. Names associated with these products include ‘smoking 
mixtures’, ‘herbal smoking mixtures’, ‘herbal incense’, ‘synthetic cannabis’, ‘legal weed’ and 
‘K2’. Common street names used include ‘magic tobacco’ in Hungary, ‘chimique’ in France, 
‘Bonsai’ in Turkey and, in Birmingham (United Kingdom), ‘Black Mamba’ or simply ‘Mamba’. 
‘Legal high’ products containing synthetic cannabinoids have been subject to innovative 
marketing approaches and are widely and openly available on the web. During the first few 
years of the phenomenon, similar products were also available in some countries in bricks-
and-mortar (‘head’ and ‘smart’) shops. 
Owing to the number and variety of synthetic cannabinoids emerging on the drug market, 
one of the challenges associated with their appearance is their naming. As the structures of 
most synthetic cannabinoids can be broken down into four components – tail, core, linker 
and linked group – the EMCDDA has introduced a semi-systematic approach to assigning 
common names to them (EMCDDA, 2017). Each component of the structure is assigned a 
code name, and the ordered combination of code names for the linked group, tail, core and 
linker allows the chemical structure of the substance to be ciphered. 
3.2. Availability and size of the market 
Synthetic cannabinoids are the largest group of new psychoactive substances monitored by 
the EMCDDA through the EU Early Warning System, with 209 identified on the drug market 
over the 13 years between 1 January 2008 and 31 December 2020. This includes 11 that 
were identified for the first time in 2020. An average of 27 cannabinoids appeared each year 
in Europe between 2011 and 2015, but since 2016 the annual number has dropped to 








FIGURE 1  
Number of synthetic cannabinoids formally notified to the EU Early Warning System 
for the first time, 2008–2020 
 
In 2019, over 18 700 seizures of synthetic cannabinoids were reported to the EU Early 
Warning System, which represents around 54 % of the total number of seizures reported 
during that year (29 % in the Member States). In the European Union, most synthetic 
cannabinoids seized were in the form of herbal plant material (5 208 cases, 112 kg) or 
powders (684 cases, 78 kg) (Figure 2). The number of seizures is unevenly distributed 
across Europe, with Turkey accounting for the large majority of the seizures of synthetic 
cannabinoids reported in 2019 (65 %). 
 
  





Seizures of synthetic cannabinoids reported to the EU Early Warning System: trends 
in (a) the number of seizures of synthetic cannabinoids and (b) the quantity seized, in 
weight (kg), 2005–2019 (all forms including powders and herbal smoking mixtures – 






In recent years, there has been a marked decrease in both the number of new synthetic 
cannabinoids appearing on the market for the first time and the quantity of powders and 
herbal material containing synthetic cannabinoids seized in the European Union (Figure 2). 
Overall, these developments may in part reflect a decrease in large-scale processing of 
synthetic cannabinoids into herbal smoking mixtures, particularly the ‘legal high’ products 
that typified a large part of the new psychoactive substances market in Europe between 2008 
and 2015. Nonetheless, relatively large amounts of bulk powders sufficient to make many 




hundreds of thousands of street doses continue to be seized at Europe’s borders each year, 
including throughout the COVID-19 pandemic. 
3.3. Response to synthetic cannabinoids 
Since 2016, a total of seven synthetic cannabinoids have been formally risk assessed by the 
EMCDDA. These were MDMB-CHMICA, in 2016; AB-CHMINACA, ADB-CHMINACA, 5F-
MDMB-PINACA and CUMYL-4CN-BINACA, during 2017; and MDMB-4en-PINACA and 4F-
MDMB-BICA, in 2020. 
Across the world, many countries have implemented legal responses to control synthetic 
cannabinoids, with many countries having used or amended existing legislation and others 
having introduced innovative legal instruments including generic definitions (by chemical 
structure or pharmacological effects). An example is given in Box 1. 
Box 1. Responses in Germany 
Legislation 
The first identification of synthetic cannabinoids in herbal blends in Germany was reported by 
Auwärter and colleagues in 2008 (Auwärter et al., 2009). The synthetic cannabinoids 
detected were JWH-018, CP-47,497 and CP-47,497-C8. In January 2009, JWH-018, CP-
47,497 and three of its homologues were scheduled under the German Narcotics Law 
because of their potential for abuse and their widespread use. In the following years, further 
synthetic cannabinoids emerged and were subsequently scheduled. Owing to the time lag 
between the emergence of new substances and their scheduling, distributors of new, 
unscheduled synthetic cannabinoids were prosecuted using the German Medicines Law. 
However, an appeal to the German Federal Supreme Court led to the European Court of 
Justice reviewing the classification of herbal products containing synthetic cannabinoids as 
medicines according to the Medicines Law. The European Court of Justice announced its 
decision on 10 July 2014 and concluded that, owing to the absence of therapeutic potential 
and the associated harms, the products could not be regarded as medicinal products as 
defined in Article 1 No 2 of Directive 2001/83/EC. The resulting regulatory gap led to the 
German ‘Act to combat the distribution of new psychoactive substances’ (NpSG) which 
became effective on 26 November 2016. In contrast to the Narcotics Law, which controls 
single substances as enumerated in the annexes of the law, the NpSG uses a generic 
approach by defining groups of substances based on their chemical structure. Particularly 
dangerous substances continue to be placed under the Narcotics Act and, if a substance 
falls under both laws, the stricter Narcotics Act is applied. The definition of a synthetic 
cannabinoid according to the NpSG comprises four structural elements: core structure, side 
chain, linker and a linked group. In the original version of the NpSG from November 2016, 
five core structural elements were defined. On 13 July 2019, an amendment came into force 
in which further core structures that had emerged on the market since 2016 were added. In 
response to the identification, shortly after, of cyclobutylmethyl side chains, which were not 
covered by the act, another amendment was prepared, which came into force on 9 July 
2020. Meanwhile, synthetic cannabinoids carrying bicyclic side chains have emerged, and a 
third amendment is currently in preparation. 





Impact on the market 
Shortly after the inclusion of recently emerged synthetic cannabinoids in the annexes of the 
German Narcotics Act, new substances with structural modifications appeared on the 
market, presumably as a response by producers to the control measures. Common 
strategies were the substitution of a hydrogen atom by a fluorine atom at the terminal 
position of the side chain or modifications at the linked group. 
In December 2016, Angerer et al. (2018a) test-purchased herbal smoking mixtures 
containing the synthetic cannabinoid CUMYL-PeGACLONE, which was not covered by the 
NpSG at that time. Furthermore, other synthetic cannabinoids with core structures not 
covered by the NpSG emerged on the German drug market, such as those containing 7-
azaindole cores. CUMYL-PeGACLONE was added to the annex of the Narcotics Law in July 
2018 by an amendment. With the emergence of its fluorinated analogue (5F-Cumyl-
PeGaClone), the control measures in place were again circumvented. However, with the 
amendment to the NpSG of July 2019, azaindoles and the γ-carbolinones are now included, 
the latter by modifying the definition of the linker. 
Following the introduction of the NpSG, some new synthetic cannabinoids that are not 
covered by the generic definitions have appeared on the drug market. These gaps in the 
definitions can be closed by amendments to the NpSG. 
In the future, as producers continue their attempts to circumvent control measures in Europe 
and elsewhere, it is unclear what new synthetic cannabinoids may be developed and what 
risks they may pose to health, especially with regard to the potential introduction of remote 
structural candidates. It is important that early warning systems can detect such substances 
in a timely manner so that public health agencies can respond through timely and effective 
actions to prevent or reduce the risk of harm. 
Figure 3 shows a heat map in which the relative positivity rate of 20 selected synthetic 
cannabinoids in urine samples analysed in the Institute of Forensic Medicine Freiburg 
(Germany) is presented for 2015 to 2019, including the five compounds described in detail in 
Annex 1 of this report (i.e. CUMYL-PeGACLONE, CUMYL-5F-P7AICA/5F-CUMYL-P7AICA, 
AB-FUBINACA, AMB-FUBINACA, and 5F-MDMB-PICA). 
  




FIGURE 3  
Heat map presenting the relative positivity rate of 20 selected synthetic cannabinoids 
in urine samples analysed in the Institute of Forensic Medicine Freiburg (Germany), 
2015 to 2019 
 
3.4. Replacement 
Synthetic cannabinoids that may emerge as new psychoactive substances 
In the past, legal restrictions on synthetic cannabinoids – regardless of whether a substance-
by-substance approach or a generic approach was used – led to the continual appearance of 
structurally modified compounds, as shown by many examples, such as the γ-carbolinones 
(e.g. CUMYL-PeGACLONE) or the more recent norbornyl derivatives (e.g. Cumyl-NB-
MeGaClone, also known as Cumyl-BC-HpMeGaClone-221). A different strategy for the drug 
market could be the use of previously described ‘classical’ or ‘non-classical’ synthetic 
cannabinoids that show higher structural similarity to Δ9-THC (Howlett et al., 2002). As a 
possible reaction to the ongoing amendments to the German NpSG, O-774 (7-[(6aR,10aR)-
1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-3-yl]-7-
methyloctanenitrile) (Figure 4) has been discussed as a compound of interest in relevant 
online discussion boards. However, such structures might not be very attractive for 
producers owing to comparatively complicated and expensive syntheses. 
Another alternative might be the synthesis of synthetic cannabinoids with new, non-regulated 
core structures as described in the patent literature. For example, Diaz et al. (2017) and 
Leftheris et al. (2003) described tricyclic or bicyclic heteroaromatic compounds as depicted in 
Figure 5a and b. 




FIGURE 4  
Chemical structure of O-774 
 
 
FIGURE 5  
Potential core structures of synthetic cannabinoids that might be used for the 
production of new psychoactive substances, as proposed by (a) Diaz et al. (2017) and 




Although not likely, other strategies could include targeting the degradation of 
endocannabinoids by inhibiting fatty acid amide hydrolase (FAAH) enzymes or the reuptake 
of endocannabinoids by uptake inhibitors such as LY-2183240 (N,N-dimethyl-5-[(4-
phenylphenyl)methyl]-1-tetrazolecarboxamide), which has already been detected in ‘legal 
high’ products in Japan (Uchiyama et al., 2014). 
Finally, the market could shift towards compounds already controlled by national law, 
depending on regulations in the producing countries. This was seen, for example, in 
Germany in the shift from 5F-ADB to 5F-MDMB-PICA and 4F-MDMB-BINACA in 2019 after a 
ban on 5F-ADB was introduced in China (Halter et al., 2020). 




4. Physical, chemical and pharmacological description 
4.1. Physical and chemical description 
Structural/chemical classification 
Synthetic cannabinoids derive from chemically quite different classes of substances, 
because binding and activation of the cannabinoid receptors can be achieved with a wide 
range of molecules. Historically, the first synthetic cannabinoids that occurred on the drug 
market were cyclohexylphenols (e.g. CP-47,497-C8) and naphthoylindoles (e.g. JWH-018). 
Substances from the broader group of aminoalkylindoles, including halogenated derivatives 
and linker groups other than carbonyl (e.g. carboxyl), were then introduced (e.g. AM-2201, 
5F-UR-144 (XLR-11), UR-144 and AM-2201 carboxylate analogue quinolinyl derivative (5F-
PB-22)). Later, indole derivatives with amino acid-like groups linked via a carboxamide linker 
(e.g. MDMB-CHMICA and 5F-MDMB-PICA) and their indazole analogues (e.g. 5F-AKB48, 
AB-CHMINACA, AB-PINACA, 5F-MDMB-PINACA (5F-ADB) and AB-FUBINACA) emerged 
and began to dominate the market. Recent developments include the introduction of cumyl 
derivatives, often linked to indoles or indazoles by a carboxamide linker (e.g. CUMYL-5F-
PINACA/5F-CUMYL-PINACA), 7-azaindoles (e.g. 5F-AB-P7AICA and CUMYL-5F-
P7AICA/5F-CUMYL-P7AICA), carbazoles (e.g. EG-018 and MDMB-CHMCZCA), γ-
carbolinones (e.g. CUMYL-PeGACLONE, 5F-Cumyl-PeGaClone, Cumyl-CH-MeGaClone) 
and compounds with modified side chains (e.g. CUMYL-CBMINACA or Cumyl-NB-
MeGaClone).  
Identification and analytical profile 
Comprehensive guidance on the recommended methods for use in forensic laboratories for 
the identification and analysis of synthetic cannabinoids in seized materials is provided in the 
United Nations Office on Drugs and Crime manual (Tettey et al., 2021). 
Physical description 
Synthetic cannabinoids in their pure form are usually described as white or yellowish, 
odourless, crystalline powders. Less pure substances may show brownish discoloration and 
have an unpleasant ‘chemical’ smell due to impurities from synthesis and solvent residues. 
Most synthetic cannabinoids are highly lipophilic and generally insoluble in water, but are 
soluble in aliphatic alcohols and non-polar organic solvents such as methanol, ethanol, 
acetonitrile, ethyl acetate, acetone or isooctane (Tettey et al., 2021). Typical octanol−water 
partition coefficients (expressed as log KOW or log P) as predicted in silico (ACD/Labs 
Percepta Platform – PhysChem Module) range between 4.5 (MDMB-CHMINACA) and 7 
(JWH-018). Melting points typically range from 55 °C (5F-AKB48) to 145 °C (AM-2233). 
Chemical stability 
In general, pure and dried synthetic cannabinoids can be regarded as chemically stable. 
However, in solutions or when heated they can be unstable, in particular when containing 




structural elements prone to hydrolysis, such as esters or primary amides, or when 
constrained ring moieties are present (e.g. UR-144). 
Hutter et al. (2013) analysed smoke condensates of cigarettes laced with the synthetic 
cannabinoid AM-2201 and found small amounts of JWH-018 and JWH-022 as thermal 
degradation products. In another study, smoking of 3,5-AB-CHMFUPPYCA (AB-
CHMFUPPYCA) was shown to result in thermal cleavage of the terminal amide (Franz et al., 
2017a). A further study, by Franz et al. (2016), showed that 5F-PB-22 (AM-2201 carboxylate 
analogue quinolinyl derivative) and AB-CHMINACA undergo ester and amide cleavage, 
respectively, when smoked, and it was highlighted that the cleavage products were also 
formed during metabolism, leading to the potential for misinterpretation of results, particularly 
of hair analysis. Nash et al. (2019) recently showed that CUMYL-PeGACLONE is thermally 
degraded by loss of the cumyl moiety. 
Kneisel et al. (2013) tested the stability of 11 synthetic cannabinoids in oral fluid stored in 
glass or polypropylene tubes. They pointed out that adsorption at the plastic surface might 
lead to considerable loss of analytes. Hess et al. (2017) investigated the freeze–thaw stability 
of 82 synthetic cannabinoids and found that most were stable in spiked serum samples for at 
least 1 month at – 20 °C when undergoing three freeze–thaw cycles. However, substances 
of the ‘AMB’ and the ‘SDB’ type showed instability at higher temperatures, probably due to 
hydrolysis (Hess et al., 2017). Fort et al. (2017) investigated the stability of 5F-UR-144 (XLR-
11), UR-144, AB-PINACA and AB-FUBINACA in spiked human whole-blood specimens. 
They found all analytes to be stable for at least 12 weeks when stored frozen (– 20 °C). 
However, stored at ambient temperature (22 °C) or refrigerated (4 °C), 5F-UR-144 (XLR-11), 
but not the other three analytes, showed significant degradation. Kevin et al. (2019a) 
investigated the thermal degradation of various carboxamide synthetic cannabinoids 
(CUMYL-PICA, 5F-CUMYL-PICA (CUMYL-5F-PICA), AMB-FUBINACA, MDMB-FUBINACA, 
NNEI (AM-6527) and MN-18) and found a range of potentially toxic degradants 
(naphthalene, 1-naphthylamine, toluene and cyanide) at the temperatures typically reached 
when smoking herbal material. Stability varied among the compounds investigated, with 
some showing ‘extensive degradation’ at temperatures between 400 and 600 °C. 
Analytical profile 
Owing to the presence of conjugated π-electron systems, synthetic cannabinoids can 
generally be detected by ultraviolet (UV) spectroscopy; however, UV spectra can be very 
similar for compounds with the same chromophore, which then requires a chromatographic 
separation for unambiguous identification. Mass spectrometric techniques, nuclear magnetic 
resonance (NMR) and infrared or Raman spectroscopy are also suitable for identification. 
It is reported that heating synthetic cannabinoids containing a tetramethylcyclopropyl ring, 
such as UR-144, as occurs during smoking or on exposure to high temperatures inside a gas 
chromatography–mass spectrometry (GC-MS) injection port, results in opening of the 
cyclopropyl ring, which is thermally unstable, creating the thermodynamic product 2,3,3-
trimethyl-1-butene side chain (Adamowicz et al., 2013; Eckre et al., undated; Grigoryev et al., 
2013a; Kaizaki-Mitsumoto et al., 2017; Thomas et al., 2017). Thermal rearrangement 




produces two peaks with similar mass spectra when using GC-MS, and it has been 
suggested that it should be treated as a GC-MS artefact (Adamowicz et al., 2013; Kaizaki-
Mitsumoto et al., 2017). During analysis, it was confirmed that UR-144 is almost completely 
changed to its degradant by heating at 300 °C for 10 minutes (Kaizaki-Mitsumoto et al., 
2017). However, ring-opening reactions in substances containing tetramethylcyclopropyl 
rings have also been reported to occur during prolonged storage and not only during heating 
(Creary et al., 1977; Thomas et al., 2017). 
It is also reported that the use of solvents such as methanol or ethanol for extraction of 
cannabimimetic quinolinyl carboxylates, such as PB-22 (JWH-018 quinolinecarboxylate 
analogue), 5F-PB-22 (AM-2201 carboxylate analogue quinolinyl derivative) and FUB-PB-22, 
may cause transesterification to occur (Tettey et al., 2021). 8-Quinolinol has been observed 
as a degradation product during GC-MS analysis (Uchiyama et al., 2013a). 
For the analysis of biological samples, liquid chromatography–tandem mass spectrometry 
(LC-MS/MS) or liquid chromatography–high-resolution mass spectrometry (LC-HRMS) is 
usually applied after liquid–liquid or solid-phase extraction. Given the immense structural 
variability of synthetic cannabinoids, the dynamic market and the expected concentrations in 
the low or sub-nanograms per millilitre range, immunoassays cannot be recommended to 
screen biological materials such as serum or urine (Franz et al., 2017b). Another group 
claimed ‘good diagnostic efficiency’ for an enzyme-linked immunosorbent assay (ELISA) kit 
(Spinelli et al., 2015), but it has to be acknowledged that the study was carried out 
retrospectively, and by the time of the study the substances available on the market had 
already changed. In contrast to blood or serum samples, in urine samples the parent 
compound is often not detectable after exposure to synthetic cannabinoids. Therefore, in 
abstinence screening, the main metabolites have to be targeted. Most laboratories perform 
an enzymatic cleavage before the analysis and target the main phase I metabolites. 
Methods and chemical precursors used for the manufacture 
Aminoalkylindoles, aminoalkylindazoles and aminoalkyl-7-azaindoles are currently the most 
prevalent synthetic cannabinoids on the drug market, and routes of synthesis are well 
described in the patent literature. Typical precursors are 1-alkylindoles, 1-alkylindazoles and 
1-alkyl-7-azaindoles (alkyl is often a pentyl, 5-fluoropentyl or cyclohexylmethyl, but can also 
be replaced by 4-fluorobenzyl or other substituents), which can be easily obtained by N-
alkylation of indole, indazole or 7-azaindole using, for example, an alkyl bromide. These can 
be acylated at C3 by a Friedel–Crafts reaction using activated carboxylic acids (e.g. 1-
naphthoyl chloride, which reacts to JWH-018 with 1-pentylindole). For the synthesis of 
carboxamide-type synthetic cannabinoids, Banister et al. (2016) described an effective 
pathway using trifluoroacetic acid anhydride for the formation of the 3-carboxy-alkylindole 
(can also be applied to indazoles and 7-azaindoles) followed by establishing the amide bond 
(e.g. the reaction of cyclohexylmethylindazole with methyl tert-leucinate leads to MDMB-
CHMINACA). 
There is no information on the actual manufacturing methods used to make the synthetic 
cannabinoids that have been identified on the drug market in Europe. However, the synthesis 




of 5F-MDMB-PICA and 5F-MDMB-PINACA, for example, has been described by Banister et 
al. (2016). The synthesis of 5F-MDMB-PICA starts with indole, which is reacted with methyl 
L-tert-leucinate, yielding (S)-5F-MDMB-PICA. The synthesis of 5F-MDMB-PINACA starts 
with methyl 1H-indazole-3-carboxylate, which is reacted with methyl L-tert-leucinate, yielding 
(S)-5F-MDMB-PINACA. The (R)-enantiomers of both substances may be synthesised under 
identical conditions using methyl D-tert-leucinate instead of methyl L-tert-leucinate. Using 
methyl tert-leucinate as a racemate would lead to the production of the racemic substance. 
The synthesis of 4F-MDMB-BICA may be carried out in the same way as the synthesis of its 
higher homologue, 5F-MDMB-PICA (EMCDDA, 2020a), and synthesis of MDMB-4en-
PINACA may be carried out in the same way as the synthesis of 5F-MDMB-PINACA 
(EMCDDA, 2020b). 
Potential precursors of 4F-MDMB-BICA are indole-3-carboxylic acid, indole-3-carboxylic acid 
methyl ester, indole, L-tert-leucine methyl ester (for the synthesis of the (S)-enantiomer) and 
1-bromo-4-fluorobutane (EMCDDA, 2020a). Potential precursors of MDMB-4en-PINACA are 
methyl 1H-indazole-3-carboxylate, 5-bromo-1-pentene and L-tert-leucine methyl ester (for 
the synthesis of the (S)-enantiomer; EMCDDA, 2020b). 
4.2. Physical and pharmaceutical form 
Currently, three main types of products containing synthetic cannabinoids are sold on the 
drug market in Europe: smoking mixtures, e-liquids and papers. Most commonly, synthetic 
cannabinoids are sprayed onto or mixed with herbal plant material or tobacco to produce a 
mixture that is then smoked as a joint or inhaled from a vaporiser or bong. In recent years, 
there has also been an increase in e-liquid products, in which a solution of the synthetic 
cannabinoid is mixed with a solvent, which is then vaped using an electronic cigarette 
(Figure 6). 
  




FIGURE 6  
E-liquid containing 5F-MDMB-PICA intended for vaping in an electronic cigarette, 
seized by Italian Carabinieri in June 2020 
 
Photo © Italian National Institute of Health. 
In addition, it appears that in some countries an increasingly common method of smuggling 
synthetic cannabinoids into prison is by means of impregnating paper with the 
cannabinoids – including letters, greeting cards, photographs, children’s drawings and 
printouts (Figure 7) (EMCDDA, 2020c). The impregnated paper is then smoked with tobacco 
or vaped using an electronic cigarette. To a lesser extent, users may prepare their own 
similar products using cannabinoids in powder form purchased from a vendor or dealer. 
Paper impregnated with synthetic cannabinoids can pose a high risk of poisoning because 
the amount of cannabinoid can vary greatly in different parts of the paper (Figure 8) (Angerer 
et al., 2018b; Norman et al., 2020). 
  




FIGURE 7  
A4-sized printouts, seized in a prison in Scotland, United Kingdom, during 2019, that 
were impregnated with MDMB-4en-PINACA and 5F-MDMB-PICA  
 
Photos © Dr Craig McKenzie, Leverhulme Research Centre for Forensic Science, University of 
Dundee, United Kingdom. 
 
FIGURE 8 
MDMB-CHMICA concentration mapping across impregnated paper showing a 
significant variation in concentration across the paper sheet  
 
Source: Originally presented by Angerer et al. (2018b) 
Photo © Forensic Toxicology Department, Institute of Forensic Medicine, Medical Center, University of 
Freiburg, Germany. 
To a much smaller extent, clothing and other textiles impregnated with synthetic 
cannabinoids have been also reported (Figure 9). 




FIGURE 9  
Socks impregnated with 4F-MDMB-BINACA seized by Lithuanian police in January 
2019 
 
Photo © Forensic Science Centre of Lithuania. 
Production of smoking mixtures 
The most common type of products containing synthetic cannabinoids are herbal smoking 
mixtures. For the production of smoking mixtures, the synthetic cannabinoids are usually 
dissolved in an organic solvent (e.g. acetone or ethanol) and sprayed onto or mixed with the 
plant material. Plants such as damiana (Turnera diffusa) and marsh-mallow (Althaea 
officinalis) are often used as the herbal basis owing to their low cost. Cement mixers have 
sometimes been used to mix the plant material with the dissolved synthetic cannabinoids 
(EMCDDA, 2016a). The soaked plant material is subsequently dried and packaged in units of 
typically 1–5 g before being sold to consumers. The process of adding the synthetic 
cannabinoids to the plant material can lead to products containing dangerous amounts of 
substances. This is because producers have to guess the amount of cannabinoids(s) to add, 
while the mixing process makes it difficult to dilute the substances sufficiently and distribute 
them consistently throughout the plant material. This can result in both products that contain 
toxic amounts of the substances in general (Ernst et al., 2017; Frinculescu et al., 2017; 
Langer et al., 2014: Langer et al., 2016) and products in which the cannabinoids are clumped 
together, forming highly concentrated pockets of the synthetic cannabinoid within the plant 
material (Frinculescu et al., 2017; Moosmann et al., 2015; Schäper, 2016). 
Production of e-liquids 
e-Liquids (liquids used in electronic vaping devices) containing synthetic cannabinoids have 
become increasingly popular over the past few years, coinciding with the wider availability 
and use of e-cigarettes and vaporisers. e‐Liquids generally consist of a polar mixture of 
propylene glycol, vegetable glycerin and ethanol; aroma compounds; and an active 
substance (e.g. synthetic cannabinoids; Münster-Müller et al., 2020). A prerequisite for the 
production of e-liquids is the solubility of the synthetic cannabinoids in the liquid base 
(usually propylene glycol and/or glycerol). Therefore, often relatively polar compounds such 
as CUMYL-5F-PINACA (5F-CUMYL-PINACA) (Angerer et al., 2019; Münster-Müller et al., 
2020) are used to prepare such formulations. 
 




Production of impregnated papers 
An increasingly common method of smuggling synthetic cannabinoids into prisons in some 
countries is by impregnating paper with the cannabinoids. The variation in synthetic 
cannabinoid concentration in these papers has been attributed to the method employed for 
the preparation of synthetic cannabinoid-impregnated papers, with the synthetic cannabinoid 
solution likely to have been added to the centre of the paper and diffusing outwards (Norman 
et al., 2020). In a simulated test, the authors demonstrated that the distribution of a synthetic 
cannabinoid across an impregnated paper was less variable when the paper was laid flat 
than when hung up to dry, which method resulted in concentrations considerably higher at 
the bottom of the papers hung up to dry (Norman et al., 2020). 
Another study investigated preparation techniques of soaking paper with synthetic 
cannabinoid solutions with a focus on visibility of this manipulation. The authors 
demonstrated that soaking paper with a 25 mg/ml MDMB-CHMICA solution did not lead to 
visible changes. In contrast, soaking with a 100 mg/ml solution produced visible anomalies 
on the paper (Angerer et al., 2018b). 
4.3. Pharmacology 
Endocannabinoid system and cannabinoid receptors 
The expression of two types of cannabinoid receptors (CB1 and CB2) plays a fundamental 
part in the human endocannabinoid system, with endogenous compounds being referred to 
as endocannabinoids (e.g. anandamide and 2-arachidonoylglycerol), which bind to these 
receptors and activate them. While CB1 receptors are most abundant in central neuronal 
tissue (with low abundance in peripheral tissue, e.g. endocrine cells), CB2 receptors are 
mainly expressed in immune cells. The psychological and physiological functions influenced 
by the modulation of CB1 receptor activity include pain perception, appetite, cognition, 
motivation, mood, memory and neuromotor functioning. The influence on these functions can 
be explained by the main localisations of CB1 receptors in the brain (the cortex, amygdala, 
hippocampus, basal ganglia and cerebellum). The psychotropic effects of cannabinoid 
receptor agonists are mainly mediated through stimulation of CB1 receptors. In contrast, 
stimulation of CB2 receptors is suggested to result in anti-inflammatory and analgesic effects, 
and CB2 receptors are regarded as a potential target for the development of medicines for 
the treatment of pain and inflammation (Greco et al., 2014). Selective agonists at CB2 
receptors are believed to have promising therapeutic potential while avoiding the adverse 
psychotropic effects of CB1 agonists. 
The cannabinoid receptors are members of the family of Gi/o protein-coupled receptors 
(GPCRs). In most tissues and cells, activation of CB1 receptors inhibits adenylyl cyclase, 
resulting in a decrease in the intracellular second messenger cyclic adenosine 
monophosphate (cAMP). Following this, depending on the type of neuron, different ion 
channels are regulated, leading to the inhibition of glutamatergic, GABAergic, glycinergic, 
cholinergic, noradrenergic or serotoninergic neurotransmission (Szabo and Schlicker, 2005). 
The inhibition of neurotransmitter release may lead to excitatory (GABAergic neurons) or 
inhibitory (glutamatergic) effects. However, evidence exists showing that some isoforms of 




the cannabinoid receptors are GsPCRs, thus leading to stimulation of adenylyl cyclase 
(Mukhopadhyay et al., 2000). Additional pathways (e.g. leading to the activation of mitogen-
activated protein kinases) have been described (Powles et al., 2005). Some studies also 
suggest that CB1 receptor activation might lead to tissue-dependent formation of intra- and 
transcellular dimers, oligomers and heterodimers as a potential explanation for different 
pharmacological outcomes in various tissues (Wager-Miller et al., 2002). Although it has 
become clear in recent decades that the endocannabinoid system regulates numerous 
somatic and mental functions, the complexity of the underlying biomolecular mechanisms 
remains to be investigated. 
Cannabinoid receptors are activated by the endogenous eicosanoids anandamide and 2-
arachidonylglycerol. While anandamide acts as a selective agonist at CB1 receptors, 2-
arachidonylglycerol shows affinity to both CB1 and CB2 receptors. The promiscuity and 
pleiotropic effects of these endocannabinoids in the central nervous system have been 
shown through experiments with CB1 receptor knockout mice by Di Marzo et al. (2000). 
Stimulation of CB1 receptors also leads to the association with intracellular β-arrestin. These 
complex molecules play a crucial role in the desensitisation of GPCRs. Binding of β-arrestin 
to a receptor initiates internalisation of the GPCR (Jin et al., 1999; Kouznetsova et al., 2002), 
a compensatory process that is believed to play a role in the development of tolerance. This 
biomolecular mechanism is often observed after the activation of CB1 receptors through 
efficacious cannabinoid receptor agonists (Hsieh et al., 1999). Case reports suggest that 
tolerance and withdrawal symptoms may develop quickly after repeated consumption of 
synthetic cannabinoids (Zimmermann et al., 2009). 
Inactivation of endocannabinoids, especially in the synaptic gap, is catalysed by FAAH 
(Deutsch and Chin, 1993). FAAH has turned out to be a possible target for the indirect 
activation of the endocannabinoid system. Inhibitors of this enzyme can potentially lead to an 
increase in endocannabinoid concentrations in the central nervous system and produce 
cannabis-like effects. In 2016, a clinical trial (phase I) investigating the clinical safety of an 
inhibitor of FAAH (BIA-102474) was halted after 4 out of 90 test subjects developed severe 
neurological injuries and one death case (Chin, 2016). The mechanism responsible for these 
adverse events remains unknown. Of note is that two FAAH inhibitors, URB597 and 
LY2183240, have been detected on the European drug market, including in ‘legal high’ 
products (EMCDDA, 2016b). 
Pharmacodynamics 
Synthetic cannabinoids are functionally similar to the main active substance of Δ9-THC found 
in Cannabis sativa. While THC acts as a partial agonist at the cannabinoid receptors, 
synthetic cannabinoids are often full agonists at CB1 and sometimes CB2 receptors (see the 
subsection ‘In vitro studies’). In the 1990s, the identification of cannabinoid receptors and 
their endogenous ligands triggered an exponential growth of studies exploring the 
endocannabinoid system. The CB1 receptor turned out to be a promising target for a wide 
range of pathological conditions. Activation of the neuronal endocannabinoid system showed 
potential for the treatment of a variety of diseases, ranging from neuropathic pain and 




neuromotor disorders, such as amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s 
disease and Huntington’s disease, to conditions such as anorexia and emesis (e.g. induced 
by chemotherapy). However, the therapeutic application of cannabinoid receptor modulators 
is still limited to pure Δ9-THC (dronabinol – active ingredient of Marinol®); nabilone (e.g. 
Cesamet®), which is chemically similar to Δ9-THC; cannabidiol (e.g. Epidiolex®); and 
Cannabis sativa (the pure herbal drug, usually the flowers of the female plant) and its 
extracts (e.g. Sativex®) (EMCDDA, 2018a). 
Although synthetic cannabinoids were first developed with the intention of treating the 
previously stated diseases and their symptoms, most of them are not used as therapeutics 
owing to their high potency at the CB1 receptor (high affinity and efficacy), which has been 
associated with psychoactive side effects with the potential for abuse, thus resulting in an 
unfavourable risk–benefit profile for medical applications. 
Since the endocannabinoid system turned out to be a promising target for the treatment of 
eating disorders such as anorexia, it seems plausible that antagonism of cannabinoid 
receptors is a reasonable approach for the treatment of obesity. Rimonabant (Acomplia®), a 
selective inverse CB1 receptor agonist, was developed for the treatment of patients with a 
body mass index of over 27 kg/m2. The approval for rimonabant as a medicine was 
withdrawn in 2008 by the European Medicines Agency owing to its psychiatric side effects 
(depression and anxiety). While rimonabant increases the likelihood of depressive and 
anxiogenic conditions, this effect is more pronounced in patients with a predisposition to 
depression, suggesting that blocking CB1 receptors through an inverse agonism is more 
likely to intensify existing conditions rather than to cause them in healthy individuals (Moreira 
and Crippa, 2009). In contrast to a neutral antagonist, rimonabant acts as an inverse agonist 
at the CB1 receptor. This means that not only does it prevent the activation of the receptor, 
but it also decreases the constitutive activity of the neuronal endocannabinoid system 
(Erdozain et al., 2012; Fong, 2014), and this may explain the serious psychiatric side effects 
of rimonabant. A decrease in CB1 receptor activity implies the presence of constitutive or 
basal activity, which was shown in both expression systems and native tissues in the 
absence of endocannabinoids (Pertwee, 2004). Although cannabinoid receptor antagonists 
did not pass the risk–benefit assessment for the treatment of obesity, they might be of 
interest for the use as antidotes in cases of synthetic cannabinoid poisoning with highly 
potent compounds (described in Section 5.1, ‘Acute toxicity’). 
In vitro studies 
The pharmacological characteristics of many synthetic cannabinoids have been investigated 
in in vitro receptor binding studies. While receptor affinity describes the ability of a ligand to 
bind to the receptor, the intrinsic activity describes the effects produced after binding and 
their strength. To illustrate this principle, rimonabant, an inverse antagonist at the CB1 
receptor, shows a high binding affinity towards CB1 receptors, but leads to no activation of 
the Gi/oPCR. Since the affinity of rimonabant to the receptor in its inactive state is much 
higher than in the active state (and vice versa for synthetic cannabinoids), the activity of CB1 
receptors is decreased in its presence. 




For the determination of receptor binding affinity, the most commonly used method is the 
competitive ligand-binding assay using radioactively labelled cannabinoid receptor agonists 
(e.g. [3H]CP-55,940, [3H-HU]243 or [3H]WIN-55,212-2). Firstly, the affinity of the competitive 
radioligand towards the respective receptor needs to be determined (KD through saturation 
binding assay). Secondly, the competitive binding assay is conducted with varying 
concentrations of the test compound in the presence of the radioligand (bound to the 
receptor), which is then replaced by the test compound in a concentration-dependent 
manner. The turning point of the resulting binding curve represents the half-maximal 
inhibitory concentration (IC50). The calculation of the Ki value is performed with the Cheng–
Prusoff equation (parameters: KD, IC50 and the concentration of radioligand). The resulting Ki 
value is a measure of the affinity of a test compound towards the receptor investigated 
(Cheng and Prusoff, 1973). 
The determination of the intrinsic activity of a test compound can be achieved through 
various assay systems. The most common methods are the [35S]GTPγS-mediated receptor 
activation assay (Nakajima et al., 2011), the fluorometric imaging plate reader (FLIPR) 
membrane potential assay (Banister et al., 2015) and the cAMP accumulation assay 
(Drabczyńska et al., 2011). These assays reveal concentration-dependent 
activation/inactivation of a GPCR caused by a ligand (half-maximal effective concentration 
(EC50) values). 
The properties of Δ9-THC in these assays are shown in Table 1. The activation of human 
CB1 receptors is observed with EC50 values between 154 nM and 171 nM. Δ9-THC acts as a 
partial agonist at the CB1 receptors (61 % maximal effect when compared to the maximal 
effect of CP-55,940). While the data regarding intrinsic activity appear to be reproducible, 
investigations on receptor-binding affinity have produced widely varying Ki values for Δ9-THC 
(3.87–80.3 nM). This finding should be kept in mind when comparing affinity data received 
under different assay conditions (human versus rat or mouse CB1 receptors; assay principle; 














TABLE 1  
Pharmacological properties of Δ9-THC towards CB1 receptors 
Receptor affinity (Ki 
in nM) 
Receptor 
activation (EC50 in 
nM) 
Receptor types Assay principle Source KD (in nM) of the 
radioligand 






Banister et al. 
(2016)  
 154 (maximal 
effect compared to 





[35S]GTPγS Own data  
3.87  Human (Chinese 
hamster ovary 
cells) 
[3H]CP-55,940 Hess et al. (2016) 2.40 
5.05  Human (Chinese 
hamster ovary 
cells) 
[3H]CP-55,940 Iwamura et al. 
(2001) 
0.57 
8.33  Mouse [3H-CP-55,940 Iwamura et al. 
(2001) 
0.70 
13.5  Rat [3H]CP-55,940 Iwamura et al. 
(2001) 
0.16 




[3H]CP-55,940 Own data — 
80.3  Rat [3H]HU243 Rhee et al. 
(1997) 
— 
40.7  Rat [3H]CP-55,940 Compton et al. 
(1992) 
0.68 





One of the most common animal models for investigating the pharmacological potency of 
cannabinoids is the observation of behavioural and physiological changes in mice. Inhibition 
of locomotor activity, antinociception, hypothermia and catalepsy are typical effects of 
cannabinoids and are known as the ‘tetrad’ of cannabimimetic effects in the mouse model. 
Another technique commonly employed in animal studies is known as the drug discrimination 
model, in which animals are trained to discriminate between two substances, placebo and 
Δ9-THC, injected intraperitoneally, using food reinforcement. The animals are first 
conditioned, using food rewards, to produce a particular response to a stimulus while under 
the influence of Δ9-THC and a different response to the same stimulus when given the 
placebo. Thus, the pharmacological effect of the cannabinoid controls the animal’s 
behaviour, making them produce the appropriate response in order to gain a food reward. 
The choice the animal takes after application of a test compound has shown to be conclusive 




for the similarity of the effects between the substance the mice were trained with and the test 
compound (e.g. synthetic cannabinoids compared to Δ9-THC; Martin et al., 1991). 
Poklis et al. (2012) studied the effects caused by inhalation of the smoke of a herbal blend 
(0.2 g), containing JWH-018 (7.2 mg) as the active ingredient, in mice. The effects observed 
in the animals tested (hypothermia, catalepsy, Straub tail and ptosis) were consistent with 
CB1 receptor activation. Similar observations after inhalation of JWH-018 (hypomotility, 
antinociception, catalepsy and hypothermia) were made by Wiley et al. (2017) and 
Wiebelhaus et al. (2012). Interestingly, in the latter study, 2.7 mg of JWH-018 produced 
antinociceptive and hypothermic effects that were similar to the effects caused by 14.8 mg of 
Δ9-THC (in marijuana). MDMB-FUBINACA and 5F-AMB (5F-AMB-PINACA) induced dose-
dependent hypothermia and bradycardia in mice (0.1–1 mg/kg body weight). The effects 
were reversed by pretreatment with the inverse CB1 receptor agonist rimonabant (Banister et 
al., 2016). 
In drug discrimination studies, Järbe et al. (2011) examined synthetic cannabinoids for their 
cannabimimetic (Δ9-THC-like) effects. JWH-018 and AM-5983 appeared to be eight times 
more potent than Δ9-THC, followed by AM-2233 (twice as potent as THC), and equipotent to 
WIN-55-212-2. While the effects of JWH-018, AM-5983 and AM-2233 were completely 
blocked by pre-administration of rimonabant, WIN-55-212-2 seemed to interact differently 
with rimonabant, probably because these two compounds bind to different sites on the CB1 
receptor. Ginsburg et al. (2012) used Δ9-THC-trained monkeys for the evaluation of JWH-018 
(which is about three to four times as potent as Δ9-THC) and JWH-073 (which is 
approximately equipotent to Δ9-THC). The duration of action was shown to be 4 hours for Δ9-
THC, 2 hours for JWH-018 and 1 hour for JWH-073. The authors concluded that these 
findings suggested a greater dependence liability for the synthetic cannabinoids investigated. 
Cannabinoids are also known to be effective antiemetic drugs. Nabilone (e.g. Cesamet®) 
and dronabinol (e.g. Marinol®) are approved for the treatment of chemotherapy-induced 
nausea and vomiting (EMCDDA, 2018a). As rats are unable to vomit, a selective measure for 
nausea in this species is the state of conditioned gaping. Studies show that gaping under the 
influence of emetic agents can be effectively erased by the application of natural and 
synthetic cannabinoids. Parker and Mechoulam (2003) studied the antiemetic effects of Δ9-
THC and the synthetic cannabinoid HU-210 in rats. They showed that these substances 
interfered with the establishment and expression of lithium-induced conditioned gaping in 
rats. Furthermore, the antiemetic effects were reversed by the application of the CB1 receptor 
antagonist rimonabant. 
Human studies 
Systematic research on the pharmacology of synthetic cannabinoids in humans has not been 
published so far. 
However, there are some reports on self-experiments conducted with synthetic 
cannabinoids. Auwärter et al. (2009) smoked a herbal blend containing JWH-018 and CP-
47,497-C8 and reported cannabis-like effects that began 10 minutes after smoking and 




lasted for about 6 hours. Teske et al. (2010) reported on a self-experiment that involved the 
smoking of about 4 mg of JWH-018 by cannabis-naive individuals, resulting in cannabis-like 
effects including thought disruptions. Further self-experiments involving the oral application 
of various synthetic cannabinoids have also been reported (e.g. Angerer et al., 2019; Hutter 
et al., 2013). In these studies, the individuals did not experience noticeable effects, probably 
because of the relatively low doses, in combination with a pronounced first-pass effect, which 
can be expected after oral administration. 
In a recent pilot study (placebo-controlled, cross-over), six volunteers (occasional cannabis 
users) vaped 2 mg or 3 mg of JWH-018 (Theunissen et al., 2018), resulting in maximum 
serum concentrations of 2.9–9.9 ng/ml (Toennes et al., 2017). The effects occurred within 
the first 2 hours after application, and no serious side effects were reported. Effects were 
mild compared with a typical recreational dose of cannabis (probably because of delivery by 
the vaping device was suboptimal) and included behavioural impairment. In a similar study, 
the same group investigated the effects of doses equivalent to 75 µg/kg body weight (up to 
6.2 mg) in 17 volunteers (Theunissen et al., 2019), resulting in a mean maximal JWH-018 
concentration of 7.5 ng/ml (1.7–22.3 ng/ml). Again, no serious side effects were experienced 
although some participants reported dissociation, amnesia and confusion. Effect size and 
cognitive impairment were more pronounced than in the pilot study, which had lower doses. 
Pharmacokinetics 
Absorption 
The most common form of consumption of synthetic cannabinoids is the inhalation of burned 
or heated plant material laced with synthetic cannabinoids (‘herbal smoking mixtures’). Such 
mixtures are usually smoked like cannabis, often combined with tobacco in a joint or a water 
pipe. Another method of administration is inhalation after vaporisation of the substance using 
a ‘vaporiser’ or by using e-liquids vaporised in electronic cigarettes. The rapid absorption 
through pulmonary alveoli usually leads to maximum concentrations (Cmax) after a few 
minutes. In an administration study with 4 mg of JWH-018, the Cmax was reached after 
5 minutes (accompanied by the occurrence of psychotropic effects; Teske et al., 2010), and 
this finding has been confirmed in other studies (Theunissen et al., 2018, 2019). 
As oral consumption can lead to unpredictable poisonings due to erratic absorption, this 
route of administration is not common among users of synthetic cannabinoids. The 
absorption of the drug is influenced by a wide range of factors (e.g. fasted versus fed state of 
the stomach, the activity of multidrug resistance proteins, passive or active transport through 
intestinal barriers and the dissolution rate of the formulation). Compared with inhalation, Cmax 
is delayed and is usually achieved between 30 minutes and several hours after 
administration (Castaneto et al., 2015). Hutter et al. (2013) observed that Cmax was reached 
approximately 1.5 hours after a single oral administration of AM-2201. A wide range of 
xenobiotics are partly eliminated after intestinal absorption by a first-pass effect in the liver, 
thereby reducing the bioavailability. Therefore, the dose needed for the desired effects after 
oral uptake exceeds the amount needed when inhaling. In the study of Hutter et al. (2013), 




5 mg of AM-2201 orally taken did not result in psychotropic effects, although – considering 
the potency of AM-2201 – this dose, if smoked, would lead to perceptible effects. 
So far, there appear to have been no reports of users of synthetic cannabinoids using 
intravenous injection or rectal application as the route of administration. However, anecdotal 
data suggest that marginalised, high-risk drug users do, on rare occasions, intravenously 
inject synthetic cannabinoids. 
Metabolism and excretion 
Synthetic cannabinoids are metabolised differently depending on their structure. The main 
metabolic reactions include the oxidation of aromatic and alkyl structures. Aromatic core 
structures such as indole, indazole, 7-azaindole and γ-carbolinone are known to be oxidised 
to mono-/dihydroxylated or dihydrodiol metabolites (Franz et al., 2019; Mogler et al., 2018a). 
Terminal hydroxyalkyl groups are often further oxidised to the corresponding carboxylic 
acids, probably catalysed by alcohol / aldehyde dehydrogenases or CYP450 enzymes 
(Chimalakonda et al., 2012; Holm et al., 2016). In some cases, further degradation of the 
carboxylic acid metabolite by decarboxylation has been observed. The γ-carbolinone-derived 
synthetic cannabinoids CUMYL-PeGACLONE and 5F-Cumyl-PeGaClone have been shown 
to be metabolised to their propionic acid metabolites by gradual alkyl chain degradation, as 
detected in human urine specimens (Mogler et al., 2018a, 2019). 
The replacement of hydrogen by a fluorine atom is a strategy commonly applied by 
manufacturers to circumvent legal restrictions and increase pharmacological potency at the 
same time (Banister et al., 2015). Defluorination of terminally fluorinated alkyl groups leads to 
ω-hydroxyalkyl metabolites. This biotransformation has been described for AM-2201 (Hutter 
et al., 2013), 5F-AKB48 (Holm et al., 2015), 5F-MDMB-PICA (Mogler et al., 2018b) and 4F-
MDMB-BINACA (Haschimi et al., 2019). Although some studies show that defluorination is 
catalysed by CYP1A2, CYP2C9 and CYP2C19 (Chimalakonda et al., 2012), the formal 
reaction of fluoroalkyl to hydroxyalkyl is chemically not an oxidation but a hydrolytic 
substitution, and the exact mechanism of defluorination remains to be investigated. In 
contrast to synthetic cannabinoids with a terminally fluorinated alkyl group, oxidation of 
substances with a non-fluorinated alkyl chain occurs only rarely at the terminal carbon atom, 
and, instead, occurs mainly at C2. Differentiation between the uptake of a fluorinated and a 
non-fluorinated analogue can therefore be achieved through analysis of these different 
hydroxylated metabolites in urine. 
The structure–metabolism relationships of the subclass of synthetic cannabinoids with valine- 
and tert-leucine-derived structures (emergence in 2012; Uchiyama et al., 2013b) have been 
described comprehensively by Franz et al. (2019). Their study included data about the in 
vitro metabolism of methyl valinates, methyl tert-leucinates, valinamides and tert-
leucinamides using a pooled human liver microsome assay. Compounds with a valine moiety 
generally underwent more pronounced hydrolysis than their tert-leucine analogues, probably 
caused by the additional methyl group leading to higher metabolic stability. Furthermore, 
hydrolytic dehalogenation of the alkyl chain was more predominant in tert-leucine analogues. 
Compounds containing a terminal methyl ester at the amino acid tail showed higher 




hydrolysis rates than their amide analogues. Methyl tert-leucinate-derived synthetic 
cannabinoids showed the highest mean relative abundance for oxidative N-dealkylation. In 
addition, dehydrogenation was predominantly observed in the valinamide derivatives, 
probably leading to energetically favoured structures (Franz et al., 2019). 
Thomsen et al. (2015) showed enzymatic activity of the carboxyl esterase 1b (CES1b) 
towards BB-22 (JWH-methylcyclohexane-8quinolinol), PB-22 (JWH-018 quinolinecarboxylate 
analogue), 5F-PB-22 (AM-2201 carboxylate analogue quinolinyl derivative) and the 
valinamide synthetic cannabinoids AB-PINACA and AB-FUBINACA. 
Glucuronidation is the most common phase II biotransformation of synthetic cannabinoids. 
5F-MDMB-P7AICA and PB-22 (JWH-018 quinolinecarboxylate analogue) / 5F-PB-22 (AM-
2201 carboxylate analogue quinolinyl derivative) are conjugated with glucuronic acid after 
phase I functionalisation (linked to the hydroxyl or carbon acid function; Richter et al., 2019; 
Wohlfarth et al., 2014). Therefore, when analysing human urine specimens, cleavage of 
glucuronic acid conjugates with β-glucuronidase is essential. 
Most synthetic cannabinoids undergo renal excretion only after metabolic transformation. 
Therefore, the detection of metabolites is essential for the unambiguous proof of exposure in 
forensic urine analysis. Nonetheless, in some cases, the parent compound is eliminated in 
urine, with the highest abundance relatively to the metabolites detected. Giorgetti et al. 
(2020) observed that 5F-AB-P7AICA, the 7-azaindole derivative of 5F-AB-PINACA, shows 
lower metabolic degradation than its indazole analogue. 
Interindividual genetic variability in metabolising enzymes and pharmacokinetic interactions 
Chimalakonda et al. (2013) described the pharmacokinetic interactions between JHW-018 
and medicines, especially regarding their metabolism. Co-administration of JWH-018 and 
inhibitors of the metabolising enzymes CYP1A2 (e.g. ciprofloxacin and fluvoxamine) or 
CYP2C9 (e.g. fluconazole and valproic acid) may lead to slower elimination of JWH-018 and 
thus to higher serum concentrations and longer lasting effects of the synthetic cannabinoids 
(Chimalakonda et al., 2013). CYP1A2 and CYP2C9 are involved in the metabolism of several 
xenobiotics and endogenous substances. Genetic polymorphisms (a poor metaboliser versus 
an extensive and ultrarapid metaboliser) may also influence serum levels of synthetic 
cannabinoids (Gunes and Dahl, 2008). Higher serum levels of synthetic cannabinoids might 
increase the risk of poisoning. 
Interactions 
Interactions regarding pharmacodynamics were described by Brents et al. (2013) for JWH-
018 and JWH-073. Combining both synthetic cannabinoids showed synergistic and additive 
effects in mice regarding analgesia and hypothermia (a leftwards shift of dose–response 
curves). Luszczki and Florek-Łuszczki (2012) described a synergistic interaction between 
pregabalin and the synthetic cannabinoid WIN-55,212-2 in a fixed dose ratio of 1:1 in the 
mouse model of acute thermal pain. The review article of Manzanares et al. (1999) 
summarises studies demonstrating the phenomena of cross-tolerance and mutual 




potentiation of hypothermia, sedation, hypotension, inhibition of motor activity and 
antinociception between cannabinoids and opioids. 
Structure–activity relationships and drug design 
Since the identification of the cannabinoid receptors CB1 and CB2 and their corresponding 
endogenous ligands (see Section 4.3, ‘Pharmacology’), numerous structurally diverse 
synthetic cannabinoids have been discovered. In addition, systematic investigations of 
structure–activity relationships have been undertaken to identify high-potency cannabinoids 
with high specificity for one or both cannabinoid receptors. 
The influence on CB1 and CB2 binding affinities of alkyl chain length at N1 of cannabimimetic 
indoles was studied by Aung et al. (2000). For this purpose, the morpholinoethyl moiety of 
WIN-55,212-2 was substituted by alkyl chains of varying length (homologous series from 
methyl to heptyl). These structural changes revealed that the pentyl chain showed the 
highest cannabinoid receptor affinity, and that the core structure of WIN-55,212-2 afforded a 
chain length of three to six carbon atoms, resulting in high binding affinity. 
The structure–activity relationship of compounds with 1-pentyl- and 1-propyl-3-(1-
naphthoyl)indole-core structures towards the cannabinoid receptors were studied by Huffman 
et al. (2005). They mainly investigated the position of the methoxy group at the naphthoyl 
residue. While methoxy substitution at C4 enhanced affinity towards the CB receptor, 
substitution at C6 and C7 seemed to have little effect, and the introduction of a 2-methoxy 
substituent completely revoked affinity towards the CB1 receptor. 
The side chain of indazole-based tert-leucine synthetic cannabinoids has a large influence on 
CB1 receptor affinity. 5F-MDMB-PINACA (5F-ADB), MDMB-FUBINACA and MDMB-
CHMINACA differ only in the presence of a 5-fluoropentyl, fluorobenzyl and cyclohexylmethyl 
group as substitution at N1 of the indazole core structure. All show high receptor binding, but 
the 5-fluoropentyl moiety (5F-MDMB-PINACA) leads to the highest potency at the CB1 
receptor (EC50 0.59 nM), followed by MDMB-FUBINACA (EC50 3.9 nM) and then MDMB-
CHMINACA (EC50 10 nM) (Banister et al., 2016). 
The work of Longworth et al. (2017) demonstrated that valine- and tert-leucine-derived 
synthetic cannabinoids, with a substituted indole or indazole core structure, exhibit high 
cannabimimetic potency in vivo and in vitro. The activity of the most abundant metabolites of 
the synthetic cannabinoids APICA (JWH-018 adamantyl carboxamide) and ADB-PINACA 
were measured in a FLIPR assay of membrane potential. The formation of a free carboxylic 
group (through oxidation of the alkyl chain or hydrolysis of amide or ester functionality) 
generally reduces pharmacological activity (Longworth et al., 2017). 
The bioisosteric substitution of hydrogen by a fluorine atom is a common strategy used by 
manufacturers to circumvent legal restrictions and increase pharmacological potency. The 
synthetic cannabinoids JWH-018, UR-144, JWH-018 quinolinecarboxylate analogue (PB-22) 
and APICA (JWH-018 adamantyl carboxamide) and their respective fluorinated analogues 
(AM-2201, 5F-UR-144 (XLR-11), AM-2201 carboxylate analogue quinolinyl derivative (5F-




PB-22) and STS-135) do all bind as agonists to the CB1 receptor. The substitution of 
hydrogen with fluorine commonly results in increased potency (Banister et al., 2015). 
Recently, the crystal structure of the human CB1 receptor (hCB1R) was revealed by Hua et 
al. (2017). The hCB1R was crystallised in a complex with the agonists AM-11542 and AM-
841, and the resulting structure provided insight into the binding mode of endogenous 
ligands, synthetic cannabinoids and naturally occurring cannabinoids. The utility of the crystal 
structure may provide a fundamental base for structure-based drug design of novel hCB1R-
targeting pharmaceuticals. 




5. Health and social risks 
The scientific data related to the acute toxic effects of synthetic cannabinoids are still limited, 
despite the relatively widespread use of these compounds, as reflected by multiple reports 
on poisonings, including deaths, involving the substances. The toxicity profile of these 
substances seems to have some similarities to that of cannabis, although more serious 
adverse health effects are often seen with the former. Some of the reasons for synthetic 
cannabinoids’ greater potential for harm compared with cannabis include their typically full 
agonism at the CB1 and CB2 receptors and the extremely high potency of many synthetic 
cannabinoids. The type and amount of synthetic cannabinoids in products can differ within 
smoking mixtures sold under the same name, and several examples of false labelling have 
been reported. In an online survey, 11 % of synthetic cannabinoid users reported having 
experienced unpredicted effects, despite consumption of the same brand of ‘Spice’ (Vandrey 
et al., 2012), which might in part be caused by inhomogeneity of the distribution of synthetic 
cannabinoids in herbal blends, producing a higher risk of overdoses even in highly 
experienced users (Moosmann et al., 2015). Unknown to users, synthetic cannabinoids have 
also been mis-sold as ecstasy/3,4-methylenedioxymethamphetamine (MDMA), other illicit 
drugs, and CBD and THC e-liquids. In some cases, this has led to severe poisoning (Allibe et 
al., 2016; Brenneman et al., 2016; Horth et al., 2018; Pap, 2016). Another concerning 
development is the increase in the identification of synthetic cannabinoids in low-THC 
cannabis products, which was first reported in Switzerland (Saferparty, 2020). Since July 
2020, the EMCDDA has received an increasing number of reports of the adulteration of 
cannabis products with highly potent synthetic cannabinoids, such as MDMB-4en-PINACA 
(EMCDDA, 2021a). Typically, the adulterated cannabis products are low-THC herbal material 
or resins. While the prevalence of these adulterated products is unknown, at least six 
countries that are part of the EU Early Warning System have reported this type of 
adulteration. In terms of look, smell and flavour, these adulterated products would be very 
difficult to distinguish from ‘genuine’ illicit cannabis products and, as a result, users may be 
unaware that they are using synthetic cannabinoids. For this reason, and as synthetic 
cannabinoids are highly potent substances, users of these products could be at high risk of 
poisoning – an issue reflected by reports of poisonings in some countries. The reason for 
adulteration is unclear, but one possibility is that low-THC industrial hemp is cheap, is widely 
available and has a similar look, smell and flavour to ‘genuine’ cannabis (making it easy to 
dupe unsuspecting users), while only a small amount of synthetic cannabinoids would be 
required to give a potent cannabis-like high. 
The high potency of synthetic cannabinoids, coupled with the unintentionally high doses that 
users are exposed to, is also responsible for outbreaks of mass poisonings involving this 
group of substances. Such outbreaks have ranged in size from four or five to hundreds of 
victims, including some deaths. While many of the outbreaks that have been reported so far 
have been in the United States, mass poisonings have also occurred in Russia, Canada and 
Europe (Adams et al., 2017; Kasper et al., 2015; Schwartz et al., 2015; Shevyrin et al., 2015; 
Springer et al., 2016; Trecki et al., 2015; Tyndall et al., 2015). Mass poisonings can rapidly 
overwhelm emergency responders and other local healthcare systems. 




For most of the synthetic cannabinoids that have emerged on the drug market, prospective 
or controlled animal or human studies are scarce or missing, although some in vitro cellular 
studies have been performed. Studies conducted in human-derived cell lines with an 
assessment of the cytotoxic/genotoxic effects of synthetic cannabinoids (JWH-018, JWH-
073, JWH-122, JWH-210, JWH-250 and AM-694) and the influences on hormone levels and 
the immune system have demonstrated only weak cytotoxicity, as such effects generally 
were observed at concentrations much higher than those expected in synthetic cannabinoid 
users (Koller et al., 2013, 2014). The compounds investigated did not cause oxidative 
damage to the DNA, but affected processes such as the synthesis of proteins and the 
homeostasis of membranes, ultimately leading to chromosomal damage. Neither 
modifications of the oestrogen levels nor abnormalities of immunomodulation were seen in 
the same study (Koller et al., 2013). Chromosomal aberrations, but no oxidation-induced 
damage, were found in a study conducted by Ferk et al. (2016) involving 5F-UR-144 (XLR-
11). Oxidative stress due to the production of reactive oxygen species in human endometrial 
stromal cells was recently demonstrated for JWH-122, UR-144 and WIN-55,212-2 (Fonseca 
et al., 2019). While this effect was compensated for by the consumption of glutathione for 
JWH-122 and UR-144, WIN-55,212-2 induced apoptotic cell death. 
5.1. Acute toxicity 
The acute toxicity of a limited number of synthetic cannabinoids has been partially studied in 
the non-clinical setting, and animal models are extremely useful both to compare adverse 
effects of synthetic cannabinoids with those produced by cannabis and to tentatively assess 
the dose at which adverse or lethal effects may occur. Furthermore, animal models can help 
to establish a tentative dose–dependence relationship. However, data mainly refer to 
relatively ‘old’ compounds, such as WIN-55,212-2, while novel substances that have 
appeared on the drug market, for example those bearing a cumyl substituent, have not been 
tested. The interpretation of animal data is complicated by differences in pharmacokinetic 
behaviour and differences in the CB receptors between various species. In addition, models 
of synthetic cannabinoid intake used in animal experiments, such as intraperitoneal 
application, do not have a direct correlate in humans. 
Clinical studies and studies involving human participants are extremely rare because of the 
unpredictability of effects, which pose a serious risk to the health of the subjects involved, 
leading to ethical issues. Therefore, evidence on acute toxicity is mainly derived from case 
reports and case series or from clinical reviews reporting on acute poisonings and/or deaths. 
One major limitation of case reports is that the exposure to synthetic cannabinoids is often 
self-reported, or only circumstantial evidence exists, rather than analytical confirmation from 
a biological sample or epidemiologically linked physical sample. 
Animal data 
Based on in vitro and animal studies, the potency of synthetic cannabinoids has been 
estimated to be 2–100 times that of Δ9-THC (Castaneto et al., 2014). 
Some preclinical studies have focused on the evaluation of the effects of synthetic 
cannabinoids on cognitive processes such as attention. Sixty rats were trained for a period of 




5 months to detect visual stimuli (a lateralised reaction time task). They were then 
administered WIN-55,212-2 intraperitoneally (1.0 or 2.5 mg/kg) and compared with a 
negative control. Accuracy, errors and response times were monitored. WIN-55,212-2 was 
shown to decrease the number of correct choices, increase omissions and increase 
response times in a dose-dependent manner; thus, it was suggested that WIN-55,212-2 
induced impairments in attention performances (Arguello and Jentsch, 2004). Deleterious 
effects on sustained attention were also seen in the trial performed by Miller et al. (2013), 
who tested rats with a two-choice reaction time task 30 minutes after intraperitoneal 
administration of 0.02, 0.04, 0.08 or 0.16 mg/kg AM 4054. Several investigations have also 
shown a significant effect of synthetic cannabinoids on working memory in rodents after the 
administration of JWH-081 and HU-210, with worsening of performances in maze-based 
tasks and of cognitive flexibility (i.e. the ability to think more than one thing simultaneously or 
to switch between concepts) after a single administration of 0.2 mg/kg HU-210 (Cohen and 
Weinstein, 2018). 
A decrease in the respiratory rate (oligopnoea) and behaviour effects (including seizure-like 
behaviour) were observed after intraperitoneal injection of 5 and 15 mg/kg MAM-2201 in 6-
week-old rats. A decrease in glutamic acid (one of the main excitatory brain 
neurotransmitters) and changes in energy metabolism were demonstrated by a mass 
spectrometry-based metabolomics study and were suggested as a possible underlying cause 
of such acute symptoms (Zaitsu et al., 2015). Within 20 minutes of acute administration of 
AM-2201 (2 mg/kg) and AB-CHMINACA (1 mg/kg), abnormal spike waves were seen in mice 
monitored by electroencephalography (EEG). Epileptic behaviour with rigidity and tonic–
clonic movements were also noted. Thirty minutes after administration, catalepsy also 
developed. These effects, which were antagonised by selective CB1, but not CB2, receptor 
antagonists, were also accompanied by a change in glutamate concentration, further 
confirming the possible role of this neurotransmitter (Funada and Takebayashi-Ohsawa, 
2018). JWH-018, administered at doses of 1.5, 2.5 and 5 mg/kg, also triggered seizures in 
mice, as recorded by EEG and videography, in a dose-dependent manner (Malyshevskaya 
et al., 2017). More recently, myoclonic jerks, ‘gasping’ reaction and other seizure-like 
activities were demonstrated in mice 2–3 minutes after the injection of a novel synthetic 
cannabinoid (CUMYL-4CN-BINACA) at doses of 0.3 and 1 mg/kg (Kevin et al., 2019b). 
In an experiment designed to test the acute toxicity of a single dose of the THJ-2201 (AM-
2201 indazole analogue), mice were administered THJ-2201 orally at a dose of 5, 50, 300 or 
2 000 mg/kg (Bakdash et al., 2018). Several symptoms, including tachycardia, seizures, 
locomotor agitation and dyspnoea developed, and their occurrence was seen in a dose-
dependent manner. By contrast, only slight modifications of the haematological parameters, 
with an increase of lymphocyte counts, were noted. Even at low doses, histological 
examination of the liver and, to a minor extent, of the kidneys of the treated mice showed 
congestion, lymphocytic infiltration and necrosis. Finally, a median lethal dose (LD50) of 
822.20 mg/kg was calculated for THJ-2201 (Bakdash et al., 2018), which points towards a 
relatively low acute toxicity. 
Taken together, these data support the hypothesis that cognitive and behaviour effects, with 
the development of seizures and agitation, respiratory depression and cardiovascular 




abnormalities, are toxic effects dose-dependently occurring after an acute intake of synthetic 
cannabinoids. 
To assess the cardiovascular effects of synthetic cannabinoids, several groups have 
experimented on isolated heart muscle preparations. For example, Bonz et al. (2003) found 
that anandamide and the synthetic cannabinoid HU-210 decreased the contractility of human 
atrial muscles when stimulated by an electrical field. More recently, incubation with CB1/2 
receptor agonists (WIN-55,212-2 and the selective CB2 agonist JWH-133) was shown by 
Maggo and Ashton (2018) to have a moderate positive chronotropic effect on isolated rat 
atria. The authors suggest that tachycardia, a well-known effect of synthetic cannabinoids 
that is believed to be mediated by central CB1 stimulation, could in part be provoked by 
myocardial CB1 receptor activation. 
In vivo studies include that by Schmid et al. (2003), who evaluated cardiovascular and 
respiratory effects in urethane-anaesthetised rats that received 0.03, 0.1, 0.3 or 1 mg/kg 
WIN-55,212-2, WIN-55,212-3 or CP-55,940 intravenously. Arterial pressure reduction, a 
decrease in heart rate and a decrease in the plasma noradrenaline levels were seen in 
animals challenged with synthetic cannabinoids, and the effects appeared to be dose related. 
Changes were accompanied by a reduction in respiratory rate, a decrease in the partial 
pressure of oxygen and a decrease in blood pH. Two out of nine animals immediately 
stopped breathing after administration of the highest dose of CP-55,940. In another study, a 
dose of 0.01 mg/kg HU-210 produced a reduction in mean blood pressure, while not 
significantly affecting heart rate, and decreased the cardiac index in anaesthetised rats 
(Wagner et al., 2001). Finally, bradycardia lasting up to 10 minutes was seen in conscious 
and freely moving rats administered WIN-55,212-2 (0.15 mg/kg), while different 
cardiovascular effects were described in spontaneously hypertensive rats (Wheal et al., 
2007). 
Some data on animals are also available owing to accidental poisonings of domestic pet 
animals with ‘Spice’ products, which may occur following the ingestion of synthetic 
cannabinoid-containing food or plant material or after the inhalation of side-stream smoke 
(Brutlag and Hommerding, 2018). Clinical signs might be reported to pet poison helplines, 
although the limitations of such data are that co-ingestants cannot be ruled out and synthetic 
cannabinoid intake is not analytically confirmed by laboratory tests in all cases reported. 
However, such data may allow for a comparison of effects in animals and humans. In a study 
involving almost 60 cases of pet (mostly canine) poisonings with synthetic cannabinoids, 
lethargy (41 %) and ataxia (52 %) were the symptoms most commonly reported, followed by 
vomiting (21 %). The sedative effect sometimes also led to a reduction in the level of 
consciousness (stupor) and to respiratory depression in 5–7 % of the cases. Depressant 
neuromotor effects were also seen, with lateral recumbency (i.e. animals were unable to rise, 
once lying down) reported in 19 % of cases. This effect was much more common after 
reported synthetic cannabinoid intake than with accidental cannabis or CBD intake. 
Agitation/irritability, mydriasis, tremors and twitching movements were described in 12–16 % 
of cases. Surprisingly, bradycardia was more frequently reported than tachycardia, occurring 
in about 16 % of cases (Brutlag and Hommerding, 2018). Effects on neuromotor and 
cardiovascular function were confirmed in one case, namely the poisoning of a dog after 




alleged exposure to a herbal smoking mixture (‘Potpourri’), with the dog developing 
progressive ataxia, marked hypothermia and bradycardia (Williams et al., 2015). 
Human data 
Data on humans are mostly available from retrospective studies of patients who seek 
medical attention after the consumption of synthetic cannabinoids, from calls to poison 
information centres or from case reports and case series of poisonings. However, these 
cases may not be fully representative, as serious poisonings are typically overrepresented. 
Although many cases of poisonings are described in the literature, it is also important to 
highlight that in only some of these cases was exposure to synthetic cannabinoids 
analytically confirmed from analysis of biological samples taken from the patients. This 
represents a further limitation in the evaluation of human data, as the reliability of 
circumstantial data is low and the co-consumption of other synthetic cannabinoids or other 
drugs (possibly without involvement of synthetic cannabinoids) cannot be excluded. In some 
cases, the intake of synthetic cannabinoids is self-reported by the patients, and test results of 
general toxicological screenings are negative (often performed only in a clinical, not a 
forensic, setting) or synthetic cannabinoids are identified in exhibits such as smoked 
products (Zawilska and Wojcieszak, 2014). Moreover, no data on the precise dose ingested 
can be obtained from such cases. 
Controlled administration studies are much rarer. In a self-experiment, 0.3 g of a ‘Spice’ 
product containing CP-47,497 was smoked, and the two participants showed increased pulse 
rates and alterations of mood and perception within 10 minutes after intake. They also 
reported cognitive impairment, which subjectively continued, with minor effects, until the next 
day (Auwärter et al., 2009). 
One male and one female volunteer smoked a cigarette containing 100 (female volunteer) 
and 150 mg (male volunteer) of a smoking mixture containing 2.9 % JWH-018 (2.9 and 
4.3 mg, equivalent to a dose of 40 and 50 µg/kg, respectively) and reported sickness, 
sedation and xerostomia immediately after the self-administration, followed by a state of light 
tiredness and exhaustion attenuating 6–12 hours after intake. Increased pulse rate, in 
accordance with previous data, mydriasis and altered pupil reaction were also noted. 
Maximum concentrations were approximately 10 ng/ml 5 minutes after smoking (Teske et al., 
2010). 
Mood and perception alterations, subjective impairment, anxiety and loss of concentration 
were also experienced by more than half of six volunteers after inhalation of 0.3 g of herbal 
blends containing JWH-018 and JWH-073. Sedation and paranoia were seen in a minority of 
cases. Tachycardia was confirmed in all subjects, who also showed a reddening of the 
conjunctivae and manifested xerostomia. A hangover effect lasted for 6–12 hours in three 
volunteers (Logan et al., 2011). 
In further experiments involving oral ingestion of 10 mg of AM-694, 26 mg of JWH-018 
adamantoyl derivative (AB-001), 5 mg of AM-2201 and 2.5 mg of 5F-AB-P7AICA, despite the 
known potency of these synthetic cannabinoids, no effects were noted (Giorgetti et al., 2020; 




Grigoryev et al., 2012; Grigoryev et al., 2013b; Hutter et al., 2013), probably because of a 
pronounced first-pass effect. 
Recently, Theunissen et al. (2021) published the results of a placebo-controlled, double-
blind, within-subjects trial in which 24 healthy participants with no history of mental illness 
inhaled vapour of placebo or JWH-018 at a dose of 75 μg/kg body weight. On average, 
participants received a total dose of 5.52 mg of JWH-018 (regarded by the authors as a 
‘moderate’ dose). The findings demonstrated that healthy volunteers who are intoxicated by 
a moderate dose of the synthetic cannabinoid JWH-018 experience pronounced psychedelic 
and dissociative symptoms and feelings of confusion. 
Some data on the toxicity of synthetic cannabinoids can also be derived from patients 
receiving chronic pain treatment. Adverse effects reported in the short-term treatment of 
chronic pain with cannabis (Vučković et al., 2018) or nabilone (McGolrick and Frey, 2018) 
were mostly mild or moderate in severity. Dizziness, drowsiness, faintness, cognitive 
impairment and fatigue were among the most commonly reported adverse effects. Nausea, 
xerostomia and cardiovascular effects such as tachycardia and hypertension also occurred. 
The reasons for withdrawal mostly consisted in the occurrence of psychiatric effects. It has to 
be stressed that Δ9-THC and nabilone are partial agonists at the CB1 receptor and that no 
such data are available for the structurally different synthetic cannabinoids that have been 
sold on the drug market and that are typically full agonists. Therefore, an extrapolation to 
synthetic cannabinoids used as ‘legal highs’ might not be justified. 
Acute poisonings 
In a retrospective study involving 29 emergency department patients, whose exposure to 
synthetic cannabinoids (mainly JWH series) was analytically confirmed, central nervous 
system and cardiovascular effects, and particularly tachycardia, were the most commonly 
reported symptoms (Hermanns-Clausen et al., 2013a). Among nervous system effects, 
restlessness/agitation was seen in 41 % of the patients. In terms of frequency, these effects 
were closely followed by changes in perception (38 %), including hyperreactivity to light and 
external stimuli, vertigo and anxiety attacks (24 % and 21 %, respectively). However, 
depression of the nervous system with somnolence, often lasting for several hours, 
confusion/disorientation and unconsciousness were also frequent (17 %, 14 % and 17 %, 
respectively). Apart from tachycardia (heart rates between 90 and 170 beats/minute), other 
common effects on cardiovascular function included hypertension (median values: 
160 mmHg systolic and 85 mmHg diastolic pressure), dyspnoea and electrocardiographic 
changes. Among gastrointestinal symptoms, nausea and vomiting were encountered in 28 % 
of patients. While the majority of these effects are consistent with those of intake of a high 
dosage of Δ9-THC, this is not the case for agitation and epileptic seizures, which seem, for 
some reason, to be more common with synthetic cannabinoids (Hermanns-Clausen et al., 
2013a). In a large survey with 15 200 responses, users reported more and stronger negative 
effects after smoking synthetic cannabinoids than after taking cannabis, with worse hangover 
effects and paranoia (Winstock and Barratt, 2013). However, prospective studies in synthetic 
cannabinoid users, especially in comparison with cannabis, have not been conducted so far; 
thus, the relative risk cannot be precisely characterised. 




According to the available studies, tachycardia (37–40 %), agitation (18–23 %), drowsiness 
(13–18.5 %), nausea/vomiting (9.9–15.7 %) and hallucinations (9.4–10.8 %) are the 
symptoms most frequently reported by poison information centres (Forrester et al., 2011; 
Hoyte et al., 2012). Despite the usefulness of such data, it has to be remembered that, in 
studies based on data from poison information centres, the exposure of patients to synthetic 
cannabinoids is often not analytically confirmed (Forrester et al., 2011; Hoyte et al., 2012). 
Neurological and respiratory effects 
Neurological symptoms can vary widely in synthetic cannabinoid-poisoned patients and 
range from agitation to various grades of central nervous system depressant effects including 
ataxia, confusion, drowsiness, dizziness, muscle weakness, numbness, slurred speech, 
paralysis, respiratory depression, lethargy and coma. 
Respiratory depression requiring intubation was reported in a series of calls to poison 
information centres, and occurred only in association with alcohol and/or benzodiazepines 
co-consumption (Forrester et al., 2011). In a survey, synthetic cannabinoid users reported 
non-serious symptoms such as a sensation of light-headedness, impairment of memory 
functions and troubles with ‘thinking clearly’ (Gunderson et al., 2014; Vandrey et al., 2012). 
Somnolence, confusion and retrograde amnesia were reported in three adolescents whose 
blood serum samples tested positive for MAM-2201 and UR-144; JWH-081 and JWH-073; 
and JWH-122 (Hermanns-Clausen et al., 2013b). Lethargy was observed in several patients 
during an outbreak in New York, United States, where analysis of serum samples confirmed 
the presence of the AMB-FUBINACA acid metabolite in 8 out of 18 patients in concentrations 
ranging from 77 to 636 ng/ml (Adams et al., 2017). Confusion, psychomotor agitation and 
psychosis were seen in five patients after smoking herbal blends containing 5F-MDMB-
PINACA (5F-ADB) and 5F-AMB-PICA (MMB-2201) (Barceló et al., 2017). 
Alon and Saint-Fleur (2017) reported on a series of four patients who presented to an 
intensive care unit with acute respiratory distress after alleged consumption of synthetic 
cannabinoids (which was not analytically confirmed). All patients required endotracheal 
intubation in the absence of a concomitant pulmonary disease and two had seizure activity. 
The respiratory distress resolved in less than 24 hours and the patients presented 
agitated/aggressive behaviour. Subsequently, aspiration pneumonia occurred in three of the 
four cases. 
In a case series of six patients who reported the use of synthetic cannabinoids, two patients 
presented to the emergency department with seizures, two with tachycardia and two with 
hallucinations (Harris and Brown, 2013). Perceptual changes and anxiety were also 
described as ‘the main psychoactive findings’ in a series of 16 adolescents seeking medical 
attention after synthetic cannabinoid use (Besli et al., 2015). Psychotic episodes may occur 
particularly in patients with known psychiatric disorders, as shown by Every-Palmer (2011) 
through semi-structured interviews with patients with a history of serious mental illness in a 
forensic facility. The data presented suggested that 9 of the 13 patients who repeatedly 
smoked a product most likely containing JWH-018 experienced symptoms consistent with 
psychotic relapse caused by JWH-018. Convulsions were witnessed in an adolescent after 
smoking a herbal blend that was analytically confirmed to contain JWH-018, JWH-081, JWH-




250 and AM-2201 (Schneir and Baumbacher, 2012). The analysis of a plasma sample 
showed JWH-methylcyclohexane-8quinolinol (BB-22), AM-2233, JWH-018 
quinolinecarboxylate analogue (PB-22), AM-2201 carboxylate analogue quinolinyl derivative 
(5F-PB-22) and JWH-122 in a patient admitted twice to hospital because of seizures after 
smoking ‘K2’ (Schep et al., 2015). Tonic–clonic seizures were also reported immediately 
after the consumption of a ‘Bonzai’ herbal blend, with serum and urine confirmation of JWH-
122, JWH-210 and JWH-018 (Hermanns-Clausen et al., 2013b). Seizures and refractory 
supraventricular tachycardia were seen in a patient hospitalised after ingestion of JWH-018, 
analytically confirmed in urine by detection of its metabolites (Lapoint et al., 2011). 
Some of the features of poisoning associated with synthetic cannabinoid consumption –
particularly loss of consciousness, respiratory depression and behavioural effects – may 
place users at additional risks, such as choking on / aspirating vomit, drowning, falling, 
hypothermia as a result of falling unconscious outside in cold weather and self-inflicted 
violence/injury (Tait et al., 2016). 
Cardiovascular effects 
Adverse cardiovascular effects associated with exposure to synthetic cannabinoids include 
tachycardia as well as a range of dysrhythmias and electrocardiographic (ECG) changes 
including bradycardia, although the latter seems to be relatively rare (1.3 % of 464 cases 
(Forrester et al., 2001) and 1.5 % of 1 898 cases (Hoyte et al., 2021)). Hypertension, chest 
pain and, to a lesser extent, hypotension are also reported by users, as determined from 
calls to poisoning centres (Forrester et al., 2011; Hoyte et al, 2012). Hypertension and 
tachycardia were demonstrated in two cases of exposure to ‘Spice’ and JWH-018 and JWH-
073 were detected in the urine (Simmons et al., 2011). Myocardial infarction was diagnosed 
based on electrocardiogram changes and elevated troponin levels in four adolescents 
seeking medical attention owing to chest pain, within 2 hours and 1 week after exposure to 
‘Spice’ products. However, exposure to cannabinoids was not confirmed analytically (Mir et 
al., 2011; McKeever et al., 2015). In addition, Young et al. (2012) reported the case of an 
individual who experienced chest pain 10 minutes after smoking a herbal blend containing 
JWH-018 and JWH-073 and in whom tachycardia and bradycardia were later confirmed in 
hospital. Analytical confirmation of the presence in urine of an adamantyl-type synthetic 
cannabinoid (not specified) was achieved in one individual with chest pain and ST-elevation 
on ECG (McIlroy et al., 2016). Cardiac arrest in a 56-year-old man with multiple 
cardiovascular risk factors (past myocardial infarction, treated with four-vessel bypass) and a 
history of increasing ‘K2’ consumption has also been reported (Ibrahim et al., 2014). Finally, 
cases of ischaemic stroke connected to synthetic cannabinoid use deemed to be 
cardioembolic in nature and triggered by cardiac arrhythmia have also been reported in the 
literature (Tait et al., 2016). 
Gastrointestinal effects 
Gastrointestinal effects of synthetic cannabinoids include nausea and vomiting, which 
according to a literature review, are symptoms seen in 13–94 % of presentations. 
Furthermore, two cases of hyperemesis following alleged synthetic cannabinoid use have 




been reported (Tait et al., 2016). While food craving and increased appetite are commonly 
experienced in association with cannabis, these were reported far less after smoking 
synthetic cannabinoids (Winstock and Barratt, 2013). Very few patients complained about 
abdominal pain, anorexia/weight loss or haematemesis (Forrester et al., 2011). 
Other effects 
Rhabdomyolysis, accompanied by psychomotor agitation and hyperthermia, has also been 
clinically assessed in cases of alleged exposure to synthetic cannabinoids (Adedinsewo et 
al., 2016; Durand et al., 2015). Rhabdomyolysis and an increase in creatinine kinase serum 
levels can be associated with kidney damage. 
The Centers for Disease Control and Prevention reported 5F-UR-144 (XLR-11) involvement 
in 7 of 16 patients diagnosed with acute kidney injury (AKI) after presenting to the emergency 
department with nausea, vomiting and flank pain within days/hours after allegedly smoking 
synthetic cannabinoids. Renal biopsy confirmed acute tubular injury and acute interstitial 
nephritis in eight of these patients, five of whom required haemodialysis. None of these 
patients died (CDC, 2013). Similarly, in another study, AKI was diagnosed in nine patients 
presenting to the emergency department with nausea and flank/abdominal pain. One clinical 
and two product samples were positive for 5F-UR-144 (XLR-11) (Buser et al., 2014). AKI 
without signs of rhabdomyolysis was seen in an agitated patient who was brought to the 
emergency department. He had allegedly consumed ‘synthetic weed’ in the previous 2 days 
(Gudsoorkar and Perez, 2015). 
Other adverse effects include anticholinergic symptoms, such as xerostomia, warm/dry skin, 
mydriasis, hyperglycaemia, hypokalaemia, hypothermia, pallor or minor dermal 
manifestations, and reddening of the conjunctivae, both in self-administration studies and in 
cases with analytically confirmed exposure to synthetic cannabinoids (Auwärter et al., 2009; 
Hermanns-Clausen et al., 2013b; Kersten and McLaughlin, 2015; Teske et al., 2010). 
Death cases 
Since their appearance on the NPS market, a number of case reports and case series of 
deaths involving synthetic cannabinoids have been published (Labay et al., 2016; Kraemer et 
al., 2019). Clearly, the number of publications cannot reflect the full dimension of the issue, 
as not all cases involving synthetic cannabinoids are detected, let alone published. 
Furthermore, since the detection of synthetic cannabinoids requires a continuous update of 
analytical methods, it is also possible that new compounds are not detected in post-mortem 
cases, depending on the type of analysis performed. Additionally, the results from 
investigations into death cases are difficult to compare, owing to differences related to a 
number of factors, such as the timing of post-mortem sampling, type of toxicological 
analyses, cause of death, co-consumption of other substances, and so on. Recently, a case 
series involving 5F-Cumyl-PeGaClone also showed that even the results of analysis of post-
mortem blood using LC-MS/MS methods fully validated for serum samples should not be 
used uncritically, owing to the possibility of strong matrix effects. Whenever possible, the 
standard addition method should be preferred for quantitation in post-mortem investigations 




(Giorgetti et al., 2020). The interpretation of blood concentrations is, per se, difficult, and this 
finding further confirms that valid interpretation affords a comprehensive analysis of all of the 
data available on the case (Angerer et al., 2016; Kraemer et al., 2019). So far, it has not 
been possible to clearly correlate synthetic cannabinoid levels in the blood with toxic effects. 
Thus, it is not possible to delineate toxic or fatal concentration ranges, as have been reported 
for many drugs and medicines, despite several intrinsic limitations (Kraemer et al., 2019). 
Labay et al. (2016) reported 25 death cases involving synthetic cannabinoids and asked 
different evaluators to assess the contributory role of the compounds involved regarding the 
cause of death. This kind of evaluation demonstrates how challenging it can be to attribute 
an interpretative weight to a substance, especially when, as for synthetic cannabinoids, 
pharmacological knowledge is limited. Indeed, in all but three cases, synthetic cannabinoids 
were deemed to have contributed to the cause of death through two or more of the following 
categories: ‘behavioural and physical’, ‘behavioural’, ‘contributed’, ‘sole poisoning’ and 
‘contribution unknown’; in only a minority of cases was there unanimous consent. 
Behavioural toxicity was the category that was most likely to lead to a fatal outcome, while 
cardiopulmonary diseases represented the most important contributing factors (Labay et al., 
2016). Finally, the authors also stated that, as the knowledge of the effects is poor and the 
blood levels do not seem to correlate well with toxic effects, caution should be exercised 
whenever synthetic cannabinoids are involved in a death case (Labay et al., 2016). 
Synthetic cannabinoids have been involved in a number of mono- and mixed-drug 
poisonings. Polydrug use cases can involve alcohol and antidepressant/neuroleptic drugs, 
such as quetiapine, amitriptyline, pregabalin, gabapentin, cathinones, amphetamines, opioids 
and dissociative anaesthetics such as diphenidine (Kraemer et al., 2019). In such cases, the 
interpretation of the contributory role of synthetic cannabinoids is further complicated, 
especially when other NPS are co-consumed. 
As clinically cardiovascular effects are among the most commonly reported harms, cardiac 
toxicity with a fatal outcome can be expected. Indeed, cardiac arrhythmia and/or cardiac 
death are frequently reported as the cause/mechanism of death in cases involving synthetic 
cannabinoids. For example, Paul et al. (2018) reported on two death cases of adolescents, 
involving AB-CHMINACA in one case and UR-144, 5F-UR-144 (XLR-11) and JWH-022 in the 
other. The drug concentrations were relatively high (8.2 ng/ml for AB-CHMINACA and 
12.3 ng/ml for UR-144). In both cases, the cause of death was deemed sudden death, 
probably due to cardiovascular toxicity, and in the first case a pre-existing cardiomyopathy 
was considered to be a contributory factor (Paul et al., 2018). An acute circulatory failure due 
to poisoning with synthetic cannabinoids was reported in a 23-year-old male who died 
3.5 hours after multiple drug intakes, having experienced a cardiopulmonary arrest. In this 
case, the presence of mepirapim (950 ng/ml), in combination with α-
ethylaminopentiophenone (EAPP) (3 100 ng/ml), was detected in serum samples collected at 
the hospital (Fujita et al., 2016). A sudden cardiac death following the intake of MDMB-
CHMICA (1.4 ng/ml, as confirmed in a serum sample collected before death) occurred in a 
22-year-old man, who was found asystolic 15 minutes after smoking a herbal blend. He 
eventually died of hypoxic brain damage (Westin et al., 2016). Shanks et al. (2016) reported 
a case of a 41-year-old female who smoked a product known as ‘Mojo’, developed agitation 




and started to behave aggressively, and then suddenly became unresponsive and died. At 
the autopsy, the cause of death was ruled to be a coronary artery thrombosis after synthetic 
cannabinoid intake (ADB-FUBINACA, 7.3 ng/ml). A potential causality was assumed 
because of the short interval between smoking and the onset of behavioural symptoms. 
In a case reported by Rojek et al. (2017), the development of behavioural symptoms is 
considered to have led to death, as a fall from height was attributed to drug-induced 
psychosis. The deceased had smoked a cigarette, manifested hallucinations and jumped out 
of a second-floor window. Post-mortem blood analysis revealed UR-144 (2.1 ng/ml) but no 
other drugs (Rojek et al., 2017). In a similar case, in which an individual who had consumed 
MDMB-CHMICA (the post-mortem blood level was 1.7 ng/ml) died after falling from a height, 
blood analysis revealed the presence of amphetamine (1 050 ng/ml), MDMA (275 ng/ml) and 
3,4-methylenedioxyamphetamine (MDA) (22 ng/ml) (Gaunitz et al., 2018). 
Poisonings involving synthetic cannabinoids may also lead to death by inducing a state of 
reduced consciousness, with subsequent aspiration of gastric content and asphyxia. This 
was the case for a 34-year-old man who was found unresponsive at his home, where three 
packages of herbal blends were retrieved. ADB-CHMINACA (MAB-CHMINACA) (6.05 ng/ml) 
was detected in post-mortem blood of the deceased, whose airway was found at autopsy to 
be occluded by a mass of material consistent with gastric content, suggesting that aspiration 
of gastric content was the cause of death (Hasegawa et al., 2015). 
In many of the reported death cases, the precise mechanism of death and/or the likely 
contribution of synthetic cannabinoids was not specified owing to a lack of circumstantial 
information or lack of knowledge of the specific drug potency/toxicity. 
Occupational exposure 
Occupational exposure to synthetic cannabinoids mainly involves seizures of synthetic 
cannabinoids by law enforcement personnel from illicit laboratories or shops, customs or 
postal seizures, and staff involved in processing the evidence. Given the large number of 
seizures, it is surprising that very little is known so far regarding occupational exposures to 
synthetic cannabinoids. 
Recently, a study was undertaken focusing on nine law enforcement agents following a raid 
on a laboratory manufacturing illicit substances in the United States, which aimed to evaluate 
the occupational health hazards from synthetic cannabinoid exposure. Disposable protective 
clothing was not used systematically and the agents ate and drank during the handling of the 
evidence. Urine samples from four agents tested positive for AB-PINACA and from six 
agents tested positive for mitragynine, whereas pre-raid collected urine samples were 
negative for both compounds (Tapp et al., 2017). Under such working conditions, seven of 
the nine agents reported symptoms such as a cough or eye/nasal/skin/throat irritation, four 
reported having felt ‘light-headed’ and ‘high’, and three reported having experienced memory 
and concentration impairment at least once during previous drug raids. 
Symptoms including dizziness, blurred vision, weakness, confusion and lethargy lasting for 
up to 2 days were reported by three customs inspectors working at an airport whose hands 




accidentally came into contact with a liquid (Dobaja et al., 2017). NMR analysis of the liquid 
revealed that it contained CUMYL-PINACA. The men presented with mydriasis and 
tachycardia and blood samples tested positive for CUMYL-PINACA. The patients recovered 
2 days after the transdermal poisoning and reported amnesia and slowed perception of time 
after exposure (Dobaja et al., 2017). 
Managing poisoning 
Currently, there is no authorised antidote that can reverse the effects of synthetic 
cannabinoids. It seems plausible that, for example, rimonabant would be effective, but a 
formal protocol for the treatment of synthetic cannabinoids poisoning has not yet been 
established. The inhomogeneity of herbal blends, which sometimes also contain other illicit 
or licit drugs, and the continual emergence of novel compounds in the market could further 
limit the possibility of identifying a suitable antidote for synthetic cannabinoids (Müller et al., 
2016). Future studies should investigate if the application of CB1 receptor antagonists might 
be an option for the treatment of synthetic cannabinoid toxicity. Studies have been conducted 
with selective CB1 antagonists, such as AM-11503. This substance was shown to reverse 
hypothermia induced by acutely administered JWH-018 (6 mg/kg) in mice, as well as to block 
tremors and convulsions caused by a ‘suprapharmacological’ dose of 18 mg/kg (Vemuri et 
al., 2019). 
Guidance on the management of acute and chronic harms of new psychoactive substances 
is provided in the Novel Psychoactive Treatment UK Network (NEPTUNE) guidelines 
(Abdulrahim and Bowden-Jones, 2015). Part V of the guidelines is dedicated to synthetic 
cannabinoids and suggests some measures for the clinical management of acute synthetic 
cannabinoid toxicity. Case reports suggest that hydration and monitoring may be sufficient 
for patients with mild to moderate poisoning. In patients with anxiety, panic attacks or 
agitation, treatment with benzodiazepines can be of benefit. Aggressive and agitated patients 
with a history of psychotic disorders might be medicated with neuroleptic agents. Owing to 
the lack of an antidote, symptomatic and supportive treatment is recommended. In the case 
of seizures, intravenous benzodiazepines have been reported to be effective. In the majority 
of cases, the effects of consumption of NPS seem to be self-limiting and can be treated 
symptomatically with intravenous fluids, benzodiazepines, supplemental oxygen and 
antiemetics. 
The management of synthetic cannabinoid poisonings might be complicated by the fact that 
typical symptoms are unspecific and might be confused with symptoms arising from other 
types of medical conditions or poisonings (Tait et al., 2016). This overlap in clinical features, 
however, has also led to the realisation that patients presenting with somnolence and 
hypoventilation, with confirmation of acute synthetic cannabinoid poisoning, might show a 
positive response to naloxone infusion, similar to patients presenting with acute opioid 
poisoning (Richards et al., 2017). In some cases, symptom improvement was reported after 
naloxone administration to patients who had reported ‘Spice’ consumption and tested 
negative for opioids. However, these results are preliminary and should viewed with caution, 
especially as it is not known if the improvement in symptoms would have occurred 
spontaneously, even without any form of pharmacotherapy (Jones et al., 2017). 




In clinical settings, diagnosis of synthetic cannabinoid poisonings should be approached with 
caution, and an in-depth study of the case is needed. Therapy remains supportive and 
symptom related (Castellanos and Gralnik, 2016). The clinical presentation alone may not be 
sufficient to demonstrate synthetic cannabinoid intake, and multiple illnesses such as 
hypoglycaemia, infections, thyroid hyperactivity, head trauma, other types of poisoning and 
mental diseases can cause similar symptoms (Tait et al., 2016). Owing to similarities in the 
clinical presentation, the treatment of acute poisoning partly overlaps with that of withdrawal 
symptoms. 
The majority of poisoned patients present with relatively mild symptoms and do not require 
hospitalisation (Tait et al., 2016; Castellanos and Gralnik, 2016). According to a study of 
synthetic cannabinoid exposures reported to the poison center, symptoms resolved within 
8 hours in 78.4 % of the cases and within 24 hours in 16.6 % of the cases (Hoyte et al., 
2012). In another survey, among users of cannabis and synthetic cannabinoids who had 
sought medical attention (n = 21), there was no difference between groups in the number of 
users who reported having been admitted to hospital or in time to recovery. The majority 
recovered within 24 hours; however, 28.6 % of synthetic cannabinoid-poisoned patients took 
2 weeks to recover (Winstock et al., 2015). Indeed, the setting in which poisoning is 
managed (i.e. in an outpatient clinic or in hospital) strongly depends on the severity of the 
symptoms (Castellanos and Gralnik, 2016). In a study performed by Hermanns-Clausen et 
al. (2013a), severe symptoms, assessed by the Poisoning Severity Score, were seen in only 
1 case out of 29. 
Monitoring is a fundamental part of the clinical management of synthetic cannabinoid 
poisonings, and should be carried out in a quiet environment, focusing on cardiovascular 
function, as poisoning commonly results in cardiovascular symptoms (often tachyarrhythmia). 
Accurate monitoring of neurological functions is also useful, given that poisoning is likely to 
result in central nervous system depression to some degree and the risk of respiratory 
depression, which may eventually require protection of the airways (Müller et al., 2016). ECG 
monitoring, pulse oximetry and a wide range of clinical and laboratory tests, depending on 
the particular case, are also suggested, including screening for other drugs of abuse and 
medications that might have been co-ingested (Müller et al., 2016). 
As shown in some retrospective case series, supportive care, with intravenous fluid 
administration and eventually potassium supplementation, is the preferred method of 
treatment (Forrester et al., 2011; Hermanns-Clausen et al., 2013a; Hoyte et al., 2012) and is 
generally sufficient in patients presenting with mild to moderate symptoms (Castellanos and 
Gralnik, 2016). Supportive care could be particularly helpful in the case of vomiting and 
dehydration or for the recovery of renal function (Müller et al., 2016). Furthermore, fluids 
were sufficient to treat hypotension and bradycardia in the cases presented by Forrester et 
al. (2011). Intravenous fluids, airways protection, cardiac monitoring and the prevention of 
rhabdomyolysis were described as the primary goals in cases of synthetic cannabinoids 
poisoning by Tait et al. (2016). 
Further therapies are influenced by the specific symptoms manifested by patients. In 
particular, benzodiazepines represent a first-line treatment for patients who present with 




agitation, anxiety, acute psychosis and seizures (Cooper, 2016), coupled with 
neuropsychiatric supportive assessment (Müller et al., 2016). Antipsychotics such as 
haloperidol and quetiapine can also be applied in cases of acute panic, hallucinations 
(Hermanns-Clausen et al., 2013a), delusion and psychosis (Müller et al., 2016). In one 
detoxification centre that administered diazepam (5–25 mg orally for, on average, 4 days) 
and quetiapine (25–475 g for, on average, 8 days) to counteract withdrawal symptoms, 
patients described antipsychotics as more effective than benzodiazepines (Macfarlane and 
Christie, 2015). Similar results were reported by Nacca et al. (2013): relief of withdrawal 
symptoms in a patient who was unresponsive to benzodiazepines, hydroxyzine and 
diphenhydramine was achieved by quetiapine administration. 
Phenobarbital, for the treatment of anxiety and prophylaxis of seizures, was used in a 
detoxification case in combination with naltrexone to control drug cravings (Rodgman et al., 
2014). 
Antiemetics can be administered in the presence of nausea or hyperemesis syndrome, 
although such compounds have not always proven beneficial (Hermanns-Clausen et al., 
2013a), as in the case reported by Ukaigwe et al. (2014), in which the use of ondansetron 
was not an effective approach. The role of gastrointestinal decontamination, in the context of 
synthetic cannabinoids poisoning, is limited by two factors: the preferential parenteral intake 
through smoking and the limited toxicity, which is self-resolving in most cases. In the series 
reported by Forrester et al. (2011), less than 5 % of patients were treated with some kind of 
decontamination (e.g. activated charcoal, lavage or irrigation/dilution). 
Finally, intravenous lipid emulsion was administered in four users rushed to the emergency 
department after reported use of synthetic cannabinoids (Aksel et al. 2015). Cardiovascular 
recovery, with normal blood pressure and pulse rate, as well as neurological recovery 
(testified by an improvement in Glasgow Coma Scale score), was seen in three out of the 
four patients, but treatment was ineffective in the one individual in whom co-consumption of 
heroin was considered likely. Intravenous administration of lipid emulsion is useful in the 
setting of highly lipophilic drugs, and intoxicated unstable patients may benefit from it, 
according to a case series published by Aksel et al. (2015). However, it has to be kept in 
mind that there is no high-level evidence to support the use of this therapy in the context of 
synthetic cannabinoids poisoning. 
5.2. Chronic toxicity 
The effects of chronic exposure to synthetic cannabinoids are largely unknown. No study has 
clearly documented the effects in humans of long-term consumption of synthetic 
cannabinoids, which – unlike cannabis – are not used as prescription medicines (with the 
exception of nabilone) (EMCDDA, 2018a). However, as already mentioned, some studies on 
animals or cell models and case reports on humans suggest that synthetic cannabinoids can 
cause certain forms of chronic toxicity. 
Koller et al. (2013) demonstrated that JWH-018, JWH-073, JWH-122, JWH-210 and AM-694 
did not show cytotoxic or genotoxic effects in various human cell lines at concentrations 
reached in the body of consumers. CP-47,497-C8 was shown to have weak cytotoxic 




properties, but is known to cause chromosomal damage (Koller et al., 2014). Bileck et al. 
(2016) found that CP-47,497-C8 has pro-inflammatory effects and can induce DNA damage. 
In another study, Koller el al. (2015) investigated the genotoxic properties of AM-2201, UR-
144, 5F-AKB48 and AM-2201-IC at elevated concentrations and demonstrated chromosomal 
damage, but no gene mutations. Tomiyama and Funada (2014) showed potential neurotoxic 
effects of eight synthetic cannabinoids (CP-55,940, CP-47,497, CP-47,497-C8, HU-210, 
JWH-018, JWH-210, AM-2201 and MAM-2201) in a mouse brain cell line. Ferk et al. (2016) 
found that 5F-UR-144 (XLR-11) and RCS-4 induced micronuclei, which are formed as a 
consequence of chromosomal aberrations. Chronic use of synthetic cannabinoids has been 
associated with a greater risk of developing a mental health disorder than use of cannabis 
(Cohen and Weinstein, 2018; Skryabin and Vinnikova, 2018), which may include 
dependence. Acute and chronic use of synthetic cannabinoids has also been associated with 
detrimental effects on cardiovascular health (Ozturk et al., 2019; Pacher et al., 2018). 
Animal data 
The cognitive effects of the long-term administration of CP-55,940 were studied in 
adolescent and adult mice, which were challenged with increasing doses of 0.15, 0.20 and 
0.30 mg/kg, each administered for 7 consecutive days. Animals were tested in tasks of object 
recognition (i.e. discrimination of a novel object from a familiar one) and object location (i.e. 
the ability to identify an object moved to a new place). While no significant effects were seen 
in adult mice, the chronic exposure to CP-55,940 in adolescence led to impairments in the 
cognitive processes investigated, involving spatial and short-term memory (Renard et al., 
2013). A lasting impairment of memory, together with the development of anxiety (as 
assessed through social interaction tests) resulting in a decrease in social interaction, was 
seen in adolescent, but not adult, rats exposed to incremental doses of CP-55,940 (0.15, 
0.20 and 0.30 mg/kg for 3, 8 and 10 days) (O’Shea et al., 2004). The effects of repeated 
administration of WIN-55,212-2 have also been studied in a number of animal models. 
Pubertal treatment with the synthetic cannabinoid at a dose of 1.2 mg/kg in a chronic 
administration setting led to deficiency in object recognition memory and in sensorimotor 
gating, which is a model to study sensory overstimulation. Cognitive fragmentation, attention 
impairments and anhedonia were also assessed in the same animal study. These functions 
are all involved in the development of schizophrenia; thus, their disruption in cases of 
adolescent chronic cannabinoid exposure indicates that synthetic cannabinoids could be 
implicated in the development of signs of mental disease (Schneider and Koch, 2003). 
Chronic administration of WIN-55,212-2 (1.2 mg/kg for 25 days) induced cellular long-term 
modifications in areas of the brain involved in the development of substance abuse and 
behavioural effects, which included the disruption of sensorimotor gating, increased motor 
activity and reduced anxious behaviour (Wegener and Koch, 2009). As many of these effects 
were proven in adolescent animals and not in adults, the chronic effects of synthetic 
cannabinoids seem to be dependent on the age at exposure and on the dose administered 
(Castaneto et al., 2014). 
 
 





While there are no data on the long-term safety of synthetic cannabinoids, long-term effects 
may partially be inferred from what happens following the prolonged consumption of 
cannabis, which is associated with an increased risk of psychosis and hallucinations 
(McGrath et al., 2010). Signs of psychosis with perceptual alterations and hallucinations were 
experienced by 10 otherwise healthy young men who reported having consumed synthetic 
cannabinoids on several occasions (from four times over 3 weeks up to daily use over 
1.5 years), and symptoms persisted for up to more than 5 months (Hurst et al., 2011). 
Heavy and prolonged cannabis consumption can also be associated with changes in brain 
volume, especially the hippocampus, which plays a major role in memory, and the amygdala, 
a region known to be crucial for emotional processing. Similar effects might be expected from 
synthetic cannabinoids, although no data on humans are available so far (Seely et al., 2012). 
Recently, Cohen et al. (2017) compared executive function in non-users, recreational 
cannabis users and synthetic cannabinoid users (38 individuals who had consumed synthetic 
cannabinoids at least 10 times in the last year without binge consumption). Computerised 
cognitive function tests, the classical Stroop word–colour task, the n-back task and a free-
recall memory task were used. In the synthetic cannabinoids group, impairment of cognitive 
function, and particularly of working memory, long-term memory and inhibitory control, 
abilities was demonstrated to be greater among synthetic cannabinoid users than among 
cannabis users (Cohen et al., 2017). 
5.3. Psychological and behavioural effects 
The typical effects of synthetic cannabinoids are similar to the known effects of cannabis and 
include relaxation, mild euphoria, lethargy, sedation, confusion, anxiety, fear, amnesia, 
derealisation, depersonalisation, psychotropic effects (changed perception), cognitive 
dysfunction, impaired motor performance and ataxia (Theunissen et al., 2021). However, 
users of synthetic cannabinoids often exhibit agitation, rather than sedation, particularly after 
consumption of higher doses. Severely intoxicated patients may also present with 
hallucinations, panic attacks and psychosis. These dose-dependent effects appear to be 
much more pronounced and severe than those of cannabis (Ford et al., 2017; Zaurova et al., 
2016). Specifically, psychotic episodes, confusion, paranoia, and aggressive and violent 
behaviour have been reported for a number of synthetic cannabinoids, including 5F-MDMB-
PINACA (EMCDDA, 2018b; WHO, 2017). 
5.4. Dependence and abuse potential 
Animal in vivo and in vitro data 
The limited data available on synthetic cannabinoids suggest a high potential for abuse and 
the potential for tolerance, dependence and withdrawal symptoms after chronic or long-term 
consumption. In general, drug discrimination studies, preference test studies and particularly 
the assessment of tolerance and reinforcement would be suitable tools to evaluate the 
dependence and abuse potential of synthetic cannabinoids. 




Chronic administration of WIN-55,212-2 (1.2 mg/kg for 25 days) induced cellular long-term 
modifications in areas of the brain involved in the development of substance abuse and 
behavioural effects, which included the disruption of sensorimotor gating, increased motor 
activity and reduced anxious behaviour (Wegener and Koch, 2009). 
Sim-Selley and Martin (2002) found that administration of escalating doses of WIN-55,212-2 
for 15 days in mice led to tolerance to acute injection of cannabinoids, as demonstrated by 
behavioural effects such as hypoactivity, nociception and hypothermia. Moreover, 
autoradiographic studies showed that [35S]GTPγS binding in all brain regions was decreased 
after chronic treatment. 
Chronic treatment with CP-55,940 (0.4 mg/kg intraperitoneally twice a day for 6.5 days) 
produced tolerance to synthetic cannabinoid-mediated analgesic effects in rats and 
downregulation of CB receptors in several parts of the brain; in addition, in the case of CB1 
receptor antagonist administration, an abstinence syndrome was precipitated (Rubino et al., 
2000). 
As for physical dependence induced by synthetic cannabinoids, a withdrawal syndrome 
could be precipitated after 4 days’ treatment with WIN-55,212-2 at any dose (1–
16 mg/kg/day) by the administration of a CB1 receptor antagonist (with symptoms occurring 
within 1 hour). Furthermore, spontaneous withdrawal symptoms were seen 24 hours after 
stopping the administration of medium doses (2–16 mg/kg/day) without the administration of 
an antagonist. In contrast, following 4 days’ treatment with Δ9-THC, only precipitated (but no 
spontaneous) withdrawal effects were demonstrated (Aceto et al., 2001), suggesting that full 
agonist synthetic cannabinoids having greater potential to produce dependence than 
cannabis. 
Human data 
The limited data available on synthetic cannabinoids suggest that the consumption of 
synthetic cannabinoids can produce tolerance and withdrawal-like symptoms when regular 
use is discontinued. These include anxiety, unstable mood, crying fits, feelings of inner 
emptiness, spatial disorientation, hyperacusis (i.e. an increased sensitivity to ordinary 
environmental sounds), somatic pain, shortness of breath, hyperventilation, intense sweating 
and sensations of motor and inner restlessness. Regular use of synthetic cannabinoids can 
lead to dependence, as seen in a case report of a patient who reported continued and 
escalating consumption of ‘Spice Gold’ for 8 months. Owing to the tolerance developed, the 
patient progressively increased the dose, finally reaching 3 g/day. Despite cognitive 
impairment and negative effects on his professional life, he continued to use the substance 
(Zimmermann et al., 2009). 
In a survey of synthetic cannabinoid users, some participants reported the use of ‘Spice’ in 
hazardous situations, inability to stop consumption despite interference with daily life and use 
for a longer period than intended (Vandrey et al., 2012). Difficulty in stopping use, together 
with the development of withdrawal symptoms, was reported by 41 of 47 patients with 
problematic daily synthetic cannabinoids use who presented to a detoxification centre 




(Macfarlane and Christie, 2015). The most commonly reported symptoms included 
agitation/irritability (83–89 %), anxiety (55%), and mood swings (55 %). Nausea and vomiting 
(44 %) and loss of appetite (17 %) were also frequently reported (Macfarlane and Christie, 
2015). Neurological examination and ECG in two patients who reported smoking 3 g of 
herbal smoking mixture daily for more than 1 year revealed severe anxiety and sinus 
tachycardia as withdrawal symptoms (Nacca et al., 2013). Nervousness, irritability, insomnia 
and impatience were also reported by 11–15 % of synthetic cannabinoid users experiencing 
withdrawal syndrome (Vandrey et al., 2012). 
5.5. Effects on ability to drive and operate machines 
Owing to the psychological and behavioural impairment they induce, synthetic cannabinoids 
can negatively affect ability to drive and safely operate machines (Capron, 2016; Griffiths and 
Griffin, 2016; Kaneko, 2017; Karinen et al., 2015; Musshoff et al., 2014; Peterson and 
Couper, 2015). Driving while under the influence of synthetic cannabinoids places users and 
others at risk of injury. 
In a case series of 36 drivers suspected of driving under the influence of drugs in 
Washington, United States, where 5F-MDMB-PINACA was the predominant psychoactive 
substance identified, 50 % of drivers were found unconscious and 28 % had been involved in 
collisions with one or more cars (Capron, 2016). 
Peterson and Couper (2015) reported 33 cases of suspected driving under the influence of 
drugs in which AB-CHMINACA was detected in blood samples. In 23 of these samples, no 
further drugs were detected. Drug recognition expert exams were performed in 10 of the 33 
cases. The most common finding was extreme lane travel with near collisions and, in nine 
cases, the driver was found unconscious or slumped over the wheel. Horizontal gaze 
nystagmus was detected in 50 % and a lack of convergence was observed in 30 % of the 
drug recognition expert cases (Peterson and Couper, 2015). 
Similarly, the operation of machinery while under the influence of synthetic cannabinoids may 
place the people who use these substances, and others, at risk of injury. 
5.6. Social risks 
While studies on the social risks of synthetic cannabinoids are rare, the available data from 
acute poisonings and self-reported user experiences suggest that the acute behavioural 
effects of synthetic cannabinoids and the associated social risks might be similar to those of 
cannabis. Such risks include negative impacts on social functioning and criminal activities, 
such as the involvement of organised crime in the manufacture, trafficking and distribution of 
the substance. Social risks connected to the long-term use of cannabis include, but are not 
restricted to, (reversibly) impaired cognitive functioning, amotivational syndrome and 
dependence. 
Of particular note is that synthetic cannabinoids are increasingly used by vulnerable groups, 
such as people in prison and people experiencing homelessness. Reports suggest that this 
has caused new health and social problems and has exacerbated existing problems among 
these groups. For example, in prisons, alongside the adverse health effects of these 




substances, such as acute poisonings, the market in synthetic cannabinoids has been linked 
to an increase in bullying and debt, as well as aggression and violence. In some cases, this 
has caused a serious threat to the overall safety and security of the prison environment 
(Blackman and Bradley, 2017; HMIP, 2015; Ralphs et al., 2017; User Voice, 2016). 
In addition, the detection of synthetic cannabinoids in cases of suspected driving under the 
influence of drugs indicates a potential for a wider risk to public safety. 




6. Extent and patterns of use, availability and potential for diffusion 
6.1. Prevalence of use 
Data on the prevalence of use of synthetic cannabinoids are based on population and 
subpopulation surveys. In population-based studies, the prevalence of current synthetic 
cannabinoid use is generally found to be less than 1 %. The most recent national surveys 
found that last year use of synthetic cannabinoids among 15- to 34-year-olds ranged from 
0.3 % in Spain and Lithuania to 0.6 % in Italy (EMCDDA, 2020d). In the case lifetime 
prevalence, the numbers can be higher and, in a population of German pupils aged 15–
18 years in the area of Frankfurt/Main, reached 5–7 % when considering use over previous 
years, although the prevalence of use in the last month was much lower (about 1 %) (Werse 
et al., 2014). In the most recent European School Survey Project on Alcohol and Other Drugs 
(ESPAD) ,in 2019, 3.1 % of students (average calculated across 20 out of 35 countries) 
reported having used synthetic cannabinoids at least once in their lifetime, ranging from 
1.1 % in Slovakia to 5.2 % in France (ESPAD Group, 2020). 
In the United States, prevalence was found to be particularly high in high school students 
during 2011, when these substances first emerged in the country, although the available data 
suggest a steady decline since then. Palamar et al. (2017) found the prevalence of use 
among a group of high school seniors in the United States to be 2.9 % (past 30-day use) for 
the period 2014–2015 (n = 7 805). In that study, synthetic cannabinoid users were more 
likely to report the use of other (non-cannabis) drugs (Palamar et al., 2017). In a sample of 
54 865 high school students (aged 13–19 years), the prevalence of past-year synthetic 
cannabinoid use was found to decrease across the study period. For example, past-year use 
among 12th grade students decreased from 11.86 % in 2011 to 4.75 % in 2015 (Keyes et al., 
2016). In another study, the prevalence of synthetic cannabinoid use among attendees of 
electronic dance music parties in New York City in 2015 (n = 682) was reported to be 16.3 % 
(Palamar et al., 2016). 
Characteristics of user groups 
Synthetic cannabinoids may be sold and used as a ‘legal’ replacement for cannabis 
(EMCDDA, 2009, 2017). Because products containing synthetic cannabinoids rarely state 
the ingredients, some users will not know that they are using synthetic cannabinoids, and 
most who do know will be unaware of what substances they are consuming. Some users 
specifically seek out synthetic cannabinoids because these have a reputation for causing 
profound intoxication and they can be comparatively cheaper than other drugs. 
It is known that synthetic cannabinoid users tend to also use cannabis (Gunderson et al., 
2014), and that polydrug use is also common among this group (Joseph et al., 2019). 
Several subpopulations of cannabis users show a relatively high prevalence of synthetic 
cannabinoids use, among them marginalised people (e.g. people experiencing 
homelessness, prisoners and injecting drug users) (Campbell and Poole, 2020; Gray et al., 
2021). People who undergo regular drug testing (such as people in drug treatment, prisoners 
and drivers) may seek out synthetic cannabinoids because some drug tests/screens will be 




unable to detect some cannabinoids (especially those that are relatively new to the drug 
market). People who use synthetic cannabinoids may also include recreational users 
(including cannabis users) and groups who experiment with substances (sometimes referred 
to as ‘psychonauts’). 
There is some evidence that, in some countries, the prevalence of synthetic cannabinoids 
use is higher among psychiatric patients, and in particular psychotic patients, than in other 
populations. Welter et al. (2017) found that 7.2 % of psychiatric patients in Germany enrolled 
in a prospective pilot study (n = 332) reported synthetic cannabinoids consumption, with 
psychotic patients showing a higher prevalence than non-psychotic patients (10 % versus 
4.5 %, respectively). 
Although limited, there is some information to suggest a recent increase in the vaping of 
synthetic cannabinoids using electronic cigarettes by young people, including teenagers, in 
some parts of Europe; in some cases, the users believed that they were using CBD or THC 
(EMCDDA, 2020c). 
6.2. Patterns of use 
Route of administration 
The most common way of using synthetic cannabinoids is by smoking either ready-to-use or 
homemade ‘smoking mixtures’ as a cigarette (‘joint’) or by using a vaporiser, ‘bong’ or pipe. 
Some synthetic cannabinoids have also been offered in the form of e-liquids for vaping in e-
cigarettes. In addition, users might also prepare e-liquids containing synthetic cannabinoids 
at home. In prison settings, papers impregnated with synthetic cannabinoids are then 
smoked with tobacco or vaped using an electronic cigarette. Other routes of administration, 
such as oral administration or by injection, appear to be rare. 
Dosage 
Doses of synthetic cannabinoids that produce psychoactive effects vary with the potency of 
the substance. Many highly potent substances, such as MDMB-CHMICA, can cause 
psychoactive effects at doses less than 1 mg. Typical doses of less potent compounds, such 
as JWH-018, have been reported to be 2–5 mg (WHO, 2014). The dosage regimens used for 
synthetic cannabinoids can differ within and between individuals depending on the tolerance 
of the user, the concomitant use of other drugs and the desired effects. The purity, amount 
and/or composition of the substance ingested are not typically known by the user. In addition, 
the actual composition of the substance may differ over time and place. 
Products containing synthetic cannabinoids rarely state the correct ingredients and/or their 
concentrations. Consequently, people who use such products will be unaware that they are 
using this substance and will be unable to obtain accurate dosage information. 
In addition, in the case of herbal smoking mixtures, the process for mixing the synthetic 
cannabinoids with the plant material can lead to heterogeneity of composition and dangerous 
amounts of the substances in the products. This is because producers have to determine 




what quantity of substances should be added, while the mixing process makes it difficult to 
dilute them sufficiently and distribute them consistently throughout the plant material. This 
can result both in products that contain toxic amounts of the substances in general (Ernst et 
al., 2017; Frinculescu et al., 2017; Langer et al., 2014: Langer et al., 2016) and in products in 
which the solid particles of synthetic cannabinoids are clumped together, forming highly 
concentrated areas (‘hot’ pockets) within the plant material (Frinculescu et al., 2017; 
Moosmann et al., 2015; Schäper, 2016). In fact, in the latter case, simply tapping a packet 
containing a smoking mixture can dislodge the substances from the plant material. Paper 
(e.g. blotters and cards) impregnated with synthetic cannabinoids can pose a similar high risk 
of poisoning because the method of soaking and drying the paper, for example, can result in 
the synthetic cannabinoid being unevenly distributed in different parts of the paper, 
sometimes forming highly concentrated sections on the paper (Norman et al., 2020). These 
issues are made worse because the products are smoked or vaped, allowing the substances 
to be rapidly absorbed into the bloodstream and to reach the central nervous system and 
other parts of the body to cause their effects. Accounts from patients and people who witness 
poisonings suggest that, in some cases, a small number of puffs from a cigarette (‘joint’) 
have been sufficient to cause severe or even fatal poisoning. 
Together, these factors, coupled with the typically high potency of synthetic cannabinoids, 
make it difficult for users to control the dose that they are exposed to. This can lead to the 
unintentional administration of a toxic dose. 
6.3. Availability, supply and involvement of organised crime 
The overall availability of synthetic cannabinoids on the market remains high, despite legal 
steps taken in many European countries and elsewhere. During the first years of the 
phenomenon, open sale in bricks-and-mortar head shops was permitted in some countries, 
but as result of the implementation of legal restrictions this practice has been stopped, or 
severely restricted, in many countries. Herbal smoking mixtures can be obtained from online 
retailers but may be also be acquired through dealer networks or from friends. The supply of 
bulk quantities of synthetic cannabinoids (pure substances) that are used to make products 
such as smoking mixtures and e-liquids largely appears to be from companies based in 
China. 
Production 
The production of the pure substances and the manufacture of (ready-to-use) products 
containing synthetic cannabinoids such as herbal mixtures and e-liquids have to be 
differentiated. 
In general, most of the synthetic cannabinoids that emerge on the European drug market are 
patented substances originally synthesised for medical research. The majority of bulk 
powders of synthetic cannabinoids appear to be produced in laboratories based in China. 
From here, the synthetic cannabinoids are shipped to distributors, who process the powders 
into products, as well as to online retailers and, to a lesser extent, consumers in Europe and 
elsewhere (EMCDDA and Europol, 2019). 





The available information suggests that synthetic cannabinoids are typically ordered from 
chemical companies based in China, which ship the substances, typically as powders, by 
mail and courier services to distributors and retailers in Europe. Similar to other NPS, in 
some cases consignments containing synthetic cannabinoids are misdeclared or concealed 
(EMCDDA and Europol, 2019). 
Distribution among users, so called ‘social supply’, also seems to play an important role, in 
particular for polydrug users (Gunderson et al., 2014; Higgins et al., 2019; Werse et al., 
2019). 
Internet markets 
The drug market has changed significantly over the last decade. While illicit drug markets 
have in the past been located on physical locations, the internet as a drug market has 
become increasingly popular. At least initially, the majority of synthetic cannabinoids were 
offered as herbal blends, e-liquids or research chemicals via internet shops on the surface 
web. However, synthetic cannabinoids and products containing synthetic cannabinoids have 
also become available on the darknet. The shops on the surface web offer a range of 
delivery and payment options. Payment options include debit and credit cards, bank transfer 
and e-commerce payment systems. More recently, payment by cryptocurrency, such as 
bitcoin, has also been accepted. Delivery is usually by express mail and courier services, as 
well as postal services. 
Darknet markets have many similarities to marketplaces such as eBay and Amazon. As on 
the surface web, customers are able to compare and rate the various vendors and their 
products. However, in contrast to the surface web, buyers can act anonymously in the 
darknet. Both information about payment and the location of the servers that are involved in 
a transaction are concealed. Therefore, sellers’ and buyers’ privacy is better protected on the 
darknet. It is estimated that about two thirds of the offers on darknet markets are drug 
related, with the remainder related to a range of other illicit goods and services (EMCDDA 
and Europol, 2017). Darknet markets are most often global and operate in English, although 
some cater for a particular country or language group. 
While attention is often focused on the use of the darknet for drug trafficking, the use of 
mainstream applications may be equally important, and such applications are more readily 
accessible. Following the development of social platforms such as Facebook, YouTube and 
Twitter, and their widespread use among young people, these platforms are being 
increasingly used by drug suppliers and dealers (EMCDDA and Europol, 2019). 
At present, online markets are believed to account for a small proportion of the trade in illicit 
drugs, and many of the transactions are at the consumer level. However, the potential exists 
for further expansion of online drug trading. 
 




Quality of the products on the market 
Typical impurities 
Impurities are defined as compounds that were intentionally added as reactants to a 
synthesis but were not completely turned into products of the reaction. Intermediate products 
of the synthesis could also be impurities. 
Münster-Müller et al. (2020) investigated synthesis-related impurities in the synthetic 
cannabinoids CUMYL-5F-PINACA and MDMB-CHMICA. In CUMYL-5F-PINACA, 12 
synthesis-related impurities were detected during the study. Several of these impurities could 
lead back to an incomplete reaction and therefore to intermediate reaction products (e.g. the 
molecules without the fluorpentyl side chain or without the linked group). Cumylamine dimers 
and fluoropentyl indole carboxamide dimers were also detected as common impurities. 
Additionally, compounds with the fluoropentyl chain in an undesired position could be identified 
during the study. In another study by the same authors (Münster-Müller et al., 2019), impurities 
from the synthesis of MDMB-CHMICA were investigated. In this case, 15 synthesis-related 
impurities could be identified. Similar to the previous case, most impurities were undesired 
intermediate products or compounds with some moieties found in another part of the target 
molecule. Interestingly, 5F-MDMB-PICA could be detected as an impurity during this study, 
although it technically constitutes a contaminant. Oberenko et al. (2019) detected three types 
of synthesis-related impurities in a study that was conducted in the Siberian region of Russia: 
unreacted main reagents for synthesis, purification reagents (used at the final stage of 
individual synthetic cannabinoid synthesis) and supplementary reagents (e.g. pH regulators). 
Contaminants and adulterants 
In March 2018, the United States Centers for Disease Control and Prevention reported an 
outbreak of life-threatening coagulopathy associated with the consumption of synthetic 
cannabinoids. Toxicological testing indicated that the affected individuals had been exposed 
to brodifacoum, a long-acting anticoagulant rodenticide. Overall, there were at least 324 
cases of severe poisoning including eight deaths in 10 states (CDC, 2018). It was speculated 
that synthetic cannabinoid products were laced with brodifacoum to extend the ‘high’ after 
smoking, although there are no data supporting this assumption. 
On occasion, opioids (e.g. U-47,700 and furanylfentanyl) have also been identified in 
smoking mixtures / plant material. Users will be unaware of this, and the use of such opioid-
containing products could pose a risk of life-threatening respiratory depression. This risk will 
be especially high in individuals with no tolerance to opioids (Coopman and Cordonnier, 
2017). 





Synthetic cannabinoids are the largest group of new psychoactive substances monitored by 
the EMCDDA through the EU Early Warning System, with 209 reported between 2008 and 
2020. When synthetic cannabinoids first appeared on the market in Europe, around 2006, 
they were sold as legal replacements for cannabis. While this continues to be the case, they 
have also gained a reputation for having powerful intoxicating effects and, as a result, some 
users use them specifically for this reason. Although synthetic cannabinoids are used 
recreationally, in some places they are also used by people experiencing homelessness, 
prisoners and other vulnerable groups because of the profound intoxication they can cause 
while being comparatively cheaper than other drugs. They also continue to be used by those 
who are subjected to drug-testing procedures, including those in prison or undergoing drug 
treatment, as some tests cannot detect synthetic cannabinoids that have recently appeared 
on the drug market. 
In Europe, since 2015, there has been a decrease in the number of synthetic cannabinoids 
identified for the first time each year and an overall decrease in seizures of the substances 
by law enforcement agencies. In part, these changes appear to be related to a disruption in 
the ‘legal high’ trade, which for a period saw synthetic cannabinoids being sold openly as 
‘legal’ replacements to cannabis on the high street and on the internet in many countries in 
Europe. More generally, broader policy responses designed to restrict the availability of new 
psychoactive substances are also likely to have had an effect. This positive development, 
however, has taken place in the context of increasing concerns associated with the use of 
these substances. As noted, in some areas there has been an increase in use by vulnerable 
groups, such as prisoners and people experiencing homelessness. In addition, not only are 
some of the synthetic cannabinoids recently introduced to the market highly potent, but there 
are increasing reports of these substances being mis-sold or used to adulterate illicit drugs. 
For example, with the increased popularity of CBD and THC products, synthetic 
cannabinoids have been identified in e-liquids sold as CBD and THC in Europe. Another 
concerning development is the adulteration of low-THC cannabis products with synthetic 
cannabinoids. Overall, such adulterated products pose a high risk of poisoning to users. 
In the future, it can be expected that compounds with a high potency and that are easy to 
synthesise will continue to be introduced into the market. In addition, there might be a 
continuation of current efforts by manufacturers to circumvent the (chemical) definition of 
generic approaches, as has been seen for other NPS. 
The ongoing COVID-19 pandemic and the related response measures may affect, in 
unpredictable ways, existing markets in synthetic cannabinoids, their use and their patterns 
of use. It is possible that, in the event of reduced availability of cannabis in Europe, criminal 
groups, as well as people who use drugs, may use a range of replacement substances, 
including synthetic cannabinoids. 
Given the growing complexity of the NPS market and its strong links with the broader illicit 
drug market, there is a need to ensure that Europe continues to strengthen its ability to 
detect, assess and respond to existing and new threats in a timely and effective way to 




prevent or reduce the public health and social harms caused by synthetic cannabinoids, 
whether this is through detecting and responding to a specific, immediate threat or via longer 
term inputs into drug policy. The EU Early Warning System, operated by the EMCDDA and 
Europol, plays a central role in supporting national- and EU-level preparedness and 
responses to new psychoactive substances, including synthetic cannabinoids. 
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CUMYL-PeGACLONE was the first representative of synthetic cannabinoids based on a γ-
carbolinone scaffold. Structurally related compounds were originally developed by Bristol-
Myers in 2001 (Leftheris et al., 2003). CUMYL-PeGACLONE emerged on the European drug 
market in December 2016, first detected in herbal blends test-purchased by the Institute of 
Forensic Medicine, Freiburg (Germany). It has been suggested that the substance may have 
been synthesised for the German drug market in order to circumvent a new national generic 
drug law that came into force in November 2016 (called NpSG) (Angerer et al., 2018a). 
 
CUMYL-PeGACLONE 
Molecular formula C25H28N2O 
Molecular weight 372.5026 g/mol 
Monoisotopic mass 372.2202  
 
Chemical and physical description 
Chemical description and names 
International Union of Pure and Applied Chemistry (IUPAC) name(s): 5‐pentyl‐2‐(2‐
phenylpropan‐2‐yl)‐2,5‐dihydro‐1H‐pyrido[4,3‐b]indol‐1‐one; 2-(1-methyl-1-phenyl-ethyl)-5-
pentyl-pyrido[4,3-b]indol-1-one 
CUMYL-PeGACLONE is characterised by a cumyl linking group (CUMYL) and a pentyl side 
chain (Pe) attached to a γ-carbolinone core system (GACLONE). The chemical structure 
lacks an open bridge scaffold. In this compound, the frequently used carboxamide linker is 




directly attached to the indole nitrogen by an ethylene bridge, resulting in a tricyclic core 
system. 





Standard InChI Key AWHWTKXMUJLSRM-UHFFFAOYSA-N 




Chemical Abstract Service Registry 
Number (CAS RN) 2160555-55-3 
Other names SGT-151 
 
Stereochemistry 
CUMYL-PeGACLONE does not contain a chiral centre. 
Physical description 
Pure CUMYL-PeGACLONE is a crystalline solid. Melting point, boiling point or solubility data 
are not available in the literature. The substance is poorly soluble in water. 
Analytical profile 
The analytical profile of CUMYL-PeGACLONE has been described in publications using GC-
MS, LC-HRMS, NMR, and infrared and ultraviolet–visible spectroscopy (Angerer et al., 
2018a; Ernst et al., 2017). A thermal degradation product (N-pentyl-γ-carbolinone) was 
detected by Nash et al. (2019), with the product being produced in significant amounts at 
temperatures above 250 °C, which are commonly reached during smoking, the preferred 
route of administration. 
Pharmacology 
CUMYL-PeGACLONE has been shown to be a full agonist at both CB receptors, with binding 
affinities in the low nanomolar range (Ki (CB1) = 1.37 ± 0.24 nM; Ki (CB2) = 2.09 ± 0.33 nM) 
(Angerer et al., 2018a). The substance is extensively metabolised after consumption (no 
parent compound is detected in urine samples). Two main metabolites were described as 
suitable for urine screenings (hydroxylation of the core structure and hydroxylation with 
further oxidation at the pentyl side chain as the main phase I biotransformation steps) 
(Mogler et al., 2018a). No data are available in the literature describing the pharmacokinetic 
properties of CUMYL-PeGACLONE. 
In a panel of 21 synthetic cannabinoids chosen to cover a broad diversity in chemical 
structures, CUMYL-PeGACLONE was among the most potent and efficacious compounds in 




two NanoBiT® bioassays assessing CB1 receptor activation (mini-Gαi assay: EC50 = 0.07 nM 
(CP-55,940: 0.12 nM), Emax = 261 % (CP55,940 set to 100 %); β-arrestin2 assay: 
EC50 = 0.09 nM (CP-55,940: 0.48 nM), Emax = 655 % (CP-55,940 set to 100 %)) (Wouters et 
al., 2020). 
Toxicology 
Twenty-seven non-fatal and fatal poisonings involving CUMYL-PeGACLONE were reported 
by Halter et al. (2019), with serum or femoral blood concentrations ranging from 0.12 to 
13 ng/ml. In all six death cases presented, the compound was assigned a low toxicological 
significance, suggesting an alternative cause of death (Halter et al., 2019). 
Five CUMYL-PeGACLONE-related fatalities in the Northern Territory of Australia were 
recently reported by Tiemensma et al. (2021), with a concentration range in post-mortem 
blood of 0.73–3.0 ng/ml. In most cases, concurrent alcohol use and underlying 
cardiovascular disease were considered relevant factors. However, in four of the cases, the 
presence of CUMYL-PeGACLONE was considered highly significant with respect to the 
cause of death (Tiemensma et al., 2021). 
Dependence and abuse potential 
There are no data available in the literature on the potential of CUMYL-PeGACLONE to 
produce dependence or on its abuse liability. 
Epidemiology in Germany 
During the market monitoring of products test-purchased and analysed in the Institute of 
Forensic Medicine, Freiburg (Germany), CUMYL-PeGACLONE was detected in 25 % of all 
products between January and December 2017 (n = 288). Detections continued to occur 
during the first half of 2018, until it was almost completely replaced by 5F-Cumyl-PeGaClone 
after CUMYL-PeEGACLONE was scheduled under the German Narcotics Act in July 2018. 
In the following years, the compound was no longer detected. At the Institute of Forensic 
Medicine in Freiburg, CUMYL-PeGACLONE was the synthetic cannabinoid detected most 
often in serum and urine screenings in 2017 and in the first half of 2018 (own unpublished 
data). After July 2018, the prevalence dropped sharply, with only sporadic detection of the 
compound (serum) or its metabolites (urine). 
Structurally related synthetic cannabinoids 
So far, five structurally related γ-carbolinone derivatives have emerged on the synthetic 
cannabinoids market. 5F-Cumyl-PeGaCLone(5F-SGT-151) was first detected in December 
2017 in Germany after CUMYL-PeGACLONE was scheduled under the German Narcotics 
Act. Cumyl-CH-MeGaClone was reported to the EMCDDA in November 2018 by Hungary. 
Cumyl-CB-MeGaClone was formally notified by the EMCDDA on behalf of Hungary in June 
2020 and Cumyl-BC-HpMeGaClone-221 (also known as CUMYL-NB-MeGaClone) was 
formally notified on behalf of Germany in September 2020. ‘MDMB-FUBGACLONE’ is a γ-
carbolinone derivative that is sold online, although it has not been formally notified up to now. 







 5F-Cumyl-PeGaClone Cumyl-CH-MeGaClone ‘MDMB-FUBGACLONE’ 
Molecular formula C25H27FN2O C27H30N2O C23H30N2O3 
Molecular weight 390.4931 g/mol 398.5399 g/mol 382.4959 g/mol 





CUMYL-5F-P7AICA is the first synthetic cannabinoid showing a 7-azaindole core structure 
and was first reported to the EMCDDA in February 2015 by Slovenia. Synthetic cannabinoids 
comprising cumyl substituents were first mentioned in a patent application of Bowden and 
Williamson (2014). However, in this patent, no synthetic cannabinoid with a 7-azaindole core 
was mentioned. The emergence of 7-azaindole synthetic cannabinoids appears to have 
coincided with the introduction of generic NPS laws in Europe, which typically included 
variations of compounds based on indole or indazole core structures, and is an indicator of 
producers’ ability to adapt the control measures in place. 
 
CUMYL-5F-P7AICA 
Molecular formula C22H26FN3O 




Molecular weight 367.4597 g/mol 
Monoisotopic mass 367.2060  
 
Chemical and physical description 
Chemical description and names 
IUPAC name: 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-
carboxamide 
CUMYL-5F-P7AICA can be regarded as the 7-azaindole (7AI) analogue of the indazole 
carboxamide synthetic cannabinoid CUMYL-5F-PINACA (CUMYL-5F-PINACA/SGT-25). The 
position of the nitrogen in the pyridine ring was confirmed by NMR analysis (EMCDDA, 
2021b). To differentiate from possible azaindole isomers, Martek et al. (2019) proposed 1H–
15N heteronuclear multiple-bond correlation NMR as a tool for rapid and unambiguous 
identification. The first azaindole monitored by the EMCDDA (5F-PCN) was a 5-azaindole.  
 
Stereochemistry 
CUMYL-5F-P7AICA does not contain a chiral centre. 
Physical description 
Pure CUMYL-5F-P7AICA is described as a neat solid. Its melting point is 174–176 °C 
(Banister et al., 2019). Boiling point or solubility data are not available in the literature. The 
substance is poorly soluble in water. 
Analytical profile 
The analytical profile of CUMYL-5F-P7AICA has been comprehensively described in the 
literature, including routes of synthesis and GC-MS, LC-HRMS and NMR data (Asada et al., 
2018; Banister et al., 2019). 
 




Standard InChI Key MXJYOUMYJGNQEY-UHFFFAOYSA-N 




Chemical Abstract Service Registry 
Number (CAS RN) — 
Other names SGT-263 





The binding affinities and functional activities of CUMYL-5F-P7AICA were evaluated by 
Banister et al. (2019) and compared with corresponding indole and indazole analogues. 
CUMYL-5F-P7AICA showed high binding affinities and activities at both CB receptors (Ki 
(CB1) = 174 nM, EC50 (CB1) = 4.7 nM, Ki (CB2) = 75.9 nM, EC50 (CB2) = 11.3 nM), but both 
affinity and activity were lower than those of the indole and indazole analogues (Banister et 
al., 2019). Metabolism of the substance in humans was studied by Staeheli et al. (2019). 
Major in vivo biotransformation steps in human metabolism were oxidative defluorination 
followed by carboxylation, and monohydroxylation followed by sulfatation and 
glucuronidation. No data are available in the literature describing the pharmacokinetic 
properties of the substance. 
Toxicology 
One report of poisoning involving CUMYL-5F-P7AICA with unknown causality described has 
been published, by Piontek and Hannemann (2018). 
Dependence and abuse potential 
There are no data available in the literature on the potential of CUMYL-5F-P7AICA to 
produce dependence or its abuse potential. 
Epidemiology in Germany 
During the market monitoring of products test-purchased and analysed in the Institute of 
Forensic Medicine, Freiburg (Germany), CUMYL-5F-P7AICA has been detected relatively 
seldomly (in approximately 2 % of all products between 2016 and 2018 and no further 
detections since December 2020; the compound was scheduled under the German Narcotics 
Act in July 2018). In serum and urine samples screened at the Institute of Forensic Medicine, 
Freiburg, there were very few positives for the compound or its metabolites in 2017 and no 
positives thereafter (own unpublished data). There were no epidemiological data on CUMYL-
5F-P7AICA found in the literature. 
Structurally related synthetic cannabinoids 
To date, five 7-azaindole-derived synthetic cannabinoids, in addition to CUMYL-5F-P7AICA, 
have emerged on the drug market. All of them are 7-azaindole analogues of well-known 
indole- or indazole-based synthetic cannabinoids. 
 
     









P7AICA 5F-A-P7AICA AB-FUB7AICA 
Molecular 
formula C22H24N4O C20H28FN3O3 C18H25FN4O2 C23H30FN3O C20H21FN4O2 
Molecular 
weight 360.4522 g/mol 377.4530 g/mol 348.4151 g/mol 383.5022 g/mol 368.4047 g/mol 
Monoisotopic 





AB-FUBINACA was one of the first synthetic cannabinoids to emerge, in 2012, on the 
Japanese drug market and features a valinamide linker group (Uchiyama et al., 2013c). It is 
structurally closely related to AB-PINACA and other valinamide derivatives that were 
originally synthesised by Pfizer in 2009 (Buchler et al., 2009). 
 
AB-FUBINACA 
Molecular formula C20H21FN4O2 
Molecular weight 368.4047 g/mol 








Chemical and physical description 




AB-FUBINACA is an indazole carboxamide synthetic cannabinoid (INACA) with a (L)-
valinamide linker group (AB). It is the first synthetic cannabinoid with a 4-fluorobenzyl side 
chain (FUB) that was notified to the EMCDDA. 





Standard InChI Key AKOOIMKXADOPDA-KRWDZBQOSA-N 




Chemical Abstract Service Registry 
Number (CAS RN 1629062-56-1 (racemate); 1185282-01-2 ((S)-AB-FUBINACA) 
Other names — 
 
Stereochemistry 
AB-FUBINACA contains a chiral centre. It is assumed that, because of the route of synthesis 
and the availability of synthesis precursors, AB-FUBINACA occurs mainly as the (S)-
enantiomer, which can be expected to be much more potent than the (R)-enantiomer 
(Antonides et al., 2019). 
Physical description 
Pure AB-FUBINACA is a crystalline solid. Its melting point is 163.0–165.5 °C (Longworth et 
al., 2016). Boiling point and solubility data are not available in the literature. It is described as 
soluble in organic solvents (~0.5 mg/ml in a 1:1 ratio of dimethyl sulfoxide to phosphate 
buffered saline at pH 7.2; ~3, 10 and 5 mg/ml in ethanol, dimethyl sulfoxide and N,N-dimethyl 
formamide) (Cayman Chemical Company, 2019). 
Analytical profile 
In the literature, AB-FUBINACA was identified for the first time in drug products by Uchiyama 
and colleagues in 2012 using NMR, GC-MS and LC-HRMS (Uchiyama et al., 2013c). A route 
for the synthesis of AB-FUBINACA and of structurally related indole and indazole 
carboxamide-type synthetic cannabinoids has been published in the literature (Banister et al., 
2015; Longworth et al., 2016). Electrospray ionisation fragmentation pathways of 
‘FUBINACA’-type synthetic cannabinoids were recently described by Sekuła et al. (2018). 





In the studies of Banister et al. (2015), AB-FUBINACA showed high functional activity at both 
types of CB receptors (hCB1 EC50 = 1.8 nM; hCB2 EC50 = 3.2 nM). The administration of AB-
FUBINACA and structurally related synthetic cannabinoids to mice was performed by 
Canazza et al. (2017). In comparison with Δ9-THC, AB-FUBINACA was shown to be much 
more potent in the tetrad model. In higher doses, severe neurological effects, such as 
seizures, myoclonia and hyperreflexia, including the promotion of aggressiveness, were 
observed. In this study, the binding affinities of AB-FUBINACA were determined using 
Chinese hamster ovary membranes (hCB1 Ki = 0.734 ± 0.071 nM; hCB2 
Ki = 0.933 ± 0.082 nM) (Canazza et al., 2017). 
The main metabolic reaction of AB-FUBINACA was shown to be hydrolysis of the terminal 
amide function, which is mainly catalysed by carboxylesterases (Thomsen et al., 2015). This 
metabolite was also reported as the predominant biotransformation product found in human 
urine samples (Castaneto et al., 2015). 
Toxicology 
Supraventricular tachycardia and acute confusion were reported in a healthy 24-year-old 
man who ingested e-cigarette fluid purchased on the internet, which was later analysed and 
found to contain AB-FUBINACA and ADB-FUBINACA. Somnolence, confusion and agitation, 
coupled with gastrointestinal symptoms, such as vomiting, developed 30 minutes after 
consumption and required attendance at the emergency department, where the intake was 
confirmed by serum analysis (AB-FUBINACA 5.6 ng/ml and ADB-FUBINACA 15.6 ng/ml). 
The patient presented with high blood pressure, low body temperature (36.3 °C) and 
tachycardia (Lam et al., 2017). He recovered and was discharged 22 hours after admission. 
A case of fatal poisoning was reported in which a combination of EAM-2201, AB-PINACA, 
AB-FUBINACA and a synthetic cathinone (α-PVP) was identified in post-mortem samples 
(Yamagishi et al., 2018). However, AB-FUBINACA was not quantified in the blood and 
information on the case is limited. A fatality was also reported involving 2.0 ng/ml AB-
FUBINACA (Fernandez et al., 2016). A propensity for sedation, tachycardia and hypothermia 
was also seen in a case series of four patients who reported ingestion of ‘molly’ and in whom 
urine samples tested positive for AB-FUBINACA (Brenneman et al., 2016). A blood 
concentration of 0.97 ng/ml AB-FUBINACA was reported in a death case described by Hess 
et al. (2015), in combination with AB-CHMINACA (2.8 ng/ml), 5F-AMB (0.19 ng/ml), 5F-
AKB48 (0.51 ng/ml), STS-135 (0.16 ng/ml) and THJ-2201 (0.16 ng/ml). The 25-year-old male 
had a history of synthetic cannabinoid use and died from diabetic ketoacidosis. Synthetic 
cannabinoids were considered the main reason for him skipping the administration of his 
daily insulin dose (Hess et al., 2015). 
Dependence and abuse potential 
In a recent study, repeated administration of AB-FUBINACA was found to induce physical 
dependence in mice. Although mice did not develop tolerance to AB-FUBINACA or cross-
tolerance to THC, somatic precipitated withdrawal signs were observed (Trexler et al., 2020). 




Epidemiology in Germany 
During the market monitoring of products test-purchased and analysed at the Institute of 
Forensic Medicine, Freiburg, Germany (EU-funded projects SPICE, SPICE II plus and 
SPICE Profiling), AB-FUBINACA was detected mainly in 2014 (in more than 20 % of all test-
purchased products; it was scheduled under the German Narcotics Act in December 2014). 
AB-FUBINACA continued to be detected in about 4 % of all products analysed between 
December 2015 and September 2018 (n = 2 474). In 2019 and 2020, it was not detected at 
all. In urine analysis, it is usually not possible to distinguish between the consumption of AB-
FUBINACA and AMB-FUBINACA because the main metabolite of both compounds is the 
same. The common metabolite was detected in more than 60 % of all positive urine samples 
in 2014, about 35 % in 2015, more than 20 % in 2016 and about 15 % in 2013, 2017 and 
2018. In 2019, the metabolite was detected in less than 10 % of positive samples, and this 
dropped further, to about 5 %, in 2020. In serum samples, AB-FUBINACA was last detected 
in 2017 (about 3 % of the positive samples; no positives in 2019 and 2020) (own unpublished 
data). 
Structurally related synthetic cannabinoids 
Several structurally related valinamide derivatives were reported to the EMCDDA. Structural 
modifications are the exchange of the 4-fluorobenzyl group by pentyl, 5-fluoropentyl or 
cyclohexylmethyl scaffolds. 
 
   
 AB-PINACA 5F-AB-PINACA AB-CHMINACA 
Molecular formula C18H26N4O2 C18H25FN4O2 C20H28N4O2 
Molecular weight 330.4246 g/mol 348.4151 g/mol 356.4619 g/mol 












AMB-FUBINACA is structurally closely related to AB-FUBINACA, with the terminal amide 
group being replaced by a methoxy group. AMB-FUBINACA was the first synthetic 
cannabinoid with valinate linking groups to emerge on the European drug market, in 2014.  
 
AMB-FUBINACA 
Molecular formula C21H22FN3O3 
Molecular weight 383.4161 g/mol 
Monoisotopic mass 383.1645 
 
Chemical and physical description 





AMB-FUBINACA differs from AB-FUBINACA in having a methylbutanoate (AMB) scaffold. 





Standard InChI Key FRFFLYJQPCIIQB-UHFFFAOYSA-N 




Chemical Abstract Service Registry 
Number (CAS RN) 1715016-76-4 
Other names FUB-AMB, MMB-FUBINACA 
 





Like its valinamide analogue AB-FUBINACA, AMB-FUBINACA contains a chiral centre. 
Given the route of synthesis and availability of synthesis precursors, it is presumed that 
AMB-FUBINACA mainly occurs in the form of the (S)-enantiomer (Antonides et al., 2019). 
Physical description 
Pure AMB-FUBINACA is a crystalline solid. In the literature, it has also been described as a 
colourless oil (Banister et al., 2016). Melting point, boiling point or solubility data are not 
available in the literature. 
Analytical profile 
The analytical profile of AMB-FUBINACA has been described in the literature, including the 
synthetic pathway and NMR data (Banister et al., 2016). GC-MS, high-performance liquid 
chromatography time-of-flight (HPLC-TOF) and Fourier-transform infrared spectroscopy 
attenuated total reflection (FTIR-ATR) data were reported to the EMCDDA by the Slovenian 
National Focal Point (RESPONSE, 2015). 
Pharmacology 
In a study by Banister et al. (2016), AMB-FUBINACA showed functional activity at both types 
of CB receptors (hCB1 EC50 = 2.0 nM; hCB2 EC50 = 18 nM). The receptor-binding affinities 
were determined in a study by Schoeder et al. (2018) (hCB1 Ki = 0.387 ± 0.135 nM; hCB2 
Ki = 0.536 ± 0.115 nM). AMB-FUBINACA is mainly metabolised to the carboxylic acid 
metabolite by terminal methylester hydrolysis (Apirakkan et al., 2020). In a recent study, 
Finlay et al. (2019) compared the activity profile of AMB-FUBINACA with ‘traditional research 
cannabinoids’ such as CP-55,940 and Δ9-THC and found significant discrepancies in the 
activity of AMB-FUBINACA in different cellular pathways, which might be related to divergent 
physiological CB1-mediated effects of AMB-FUBINACA and other synthetic cannabinoids. 
Toxicology 
In July 2016, an outbreak of mass poisoning caused by AMB-FUBINACA occurred in New 
York, United States. Thirty-three patients presented with ‘altered mental status’, including 
lethargy and a reduction in the Glasgow Coma Scale score. AMB-FUBINACA was identified 
in a sample of product recovered from one of the patients. Metabolite of AMB-FUBINACA 
was also detected in biological samples from eight patients (Adams et al., 2017). 
Adamowicz et al. (2019) reported the fatal poisoning of a 27-year-old male involving AMB-
FUBINACA. The autopsy revealed pleural adhesions and pulmonary oedema, while samples 
collected during post-mortem examinations showed both AMB-FUBINACA and EMB-
FUBINACA in tissues but not in blood. Concentrations in solid tissues ranged from 0.2 to 
0.9 ng/ml and from 0.2 to 3.5 ng/ml, respectively (Adamowicz et al., 2019). 
 




Dependence and abuse potential 
There are no data available in the literature on the potential of AMB-FUBINACA to produce 
dependence or on its abuse potential. 
Epidemiology in Germany 
AMB-FUBINACA was regularly detected during the market monitoring of products test-
purchased and analysed in the Institute of Forensic Medicine, Freiburg (Germany), between 
2015 and 2018 (not detected in 2019 and 2020), with a maximum between 2015 and 2016 
(AMB-FUBINACA was scheduled under the German Narcotics Act in June 2016). In urine 
analysis, it is not usually possible to distinguish between consumption of AB-FUBINACA and 
AMB-FUBINACA because the main metabolite of both compounds is the same. The common 
metabolite was detected in more than 60 % of all positive urine samples in 2014, about 35 % 
in 2015, more than 20 % in 2016 and about 15 % in 2013, 2017 and 2018. In 2019, the 
metabolite was detected in less than 10 % of the positive samples, and this dropped further 
to about 5 % in 2020. In serum samples, AMB-FUBINACA was detected in about 5 to 10 % 
of the positive samples until the second half of 2019, with only sporadic detection thereafter 
(own unpublished data). 
Structurally related synthetic cannabinoids 
Several structurally related synthetic cannabinoids showing valinate moieties have been 
reported to the EMCDDA. Structural modifications include the exchange of the 4-fluorobenzyl 
group by 5-fluoropentyl or cyclohexylmethyl scaffolds and/or the replacement by the indazole 





   
 5F-AMB-PINACA AMB-CHMINACA AMB-FUBICA 
Molecular formula C19H26FN3O3 C21H29N3O3 C22H23FN2O3 
Molecular weight 363.4264 g/mol 371.4733 g/mol 382.4280 g/mol 
Monoisotopic mass 363.1958 371.2210 382.1693 






5F-MDMB-PICA emerged on the European drug market in 2016 (Mogler et al., 2018b). It 
was synthesised by Banister et al. (2016) to study the structure–activity relationship of 
synthetic cannabinoids carrying tert-leucinate scaffolds. 
 
5F-MDMB-PICA 
Molecular formula C21H29FN2O3 
Molecular weight 376.4650 g/mol 
Monoisotopic mass 376.2162 
 
Chemical and physical description 
Chemical description and names 
IUPAC name(s): methyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-
butanoate; methyl N-{[1-(5-fluoropentyl)-1H-indol-3-yl]carbonyl}-3-methylvalinate 
5F-MDMB-PICA is the indole analogue of the highly prevalent indazole carboxamide SC 5F-
ADB (5F-MDMB-PINACA). 





Standard InChI Key CHSUEEBESACQDV-GOSISDBHSA-N 




Chemical Abstract Service Registry 
Number (CAS RN) 1971007-88-1 




Other names 5F-MDMB-2201, MDMB-2201 
 
Stereochemistry 
5F-MDMB-PICA shows a chiral centre. It is assumed (based on the route of synthesis and 
the availability of synthesis precursors) that 5F-MDMB-PICA occurs mainly in the form of the 
(S)-enantiomer (Antonides et al., 2019). 
Physical description 
Pure 5F-MDMB-PICA is a crystalline solid. Its melting point is 82–84 °C (Banister et al., 
2016). Boiling point and solubility data are not available in the literature. 
Analytical profile 
The analytical profile of 5F-MDMB-PICA has been described in the literature, including the 
synthetic pathway and NMR, GC-MS, high-performance liquid chromatography with diode 
array detection (HPLC-DAD) and liquid chromatography quadrupole time of flight mass 
spectrometry (LC-QTOF-MS) data (Banister et al., 2016; Mogler et al., 2018b; Risseeuw et 
al., 2017). 
Pharmacology 
A study by Banister et al. (2016) assessed the functional activity of 5F-MDMB-PICA and 16 
other valinate and tert-leucinate synthetic cannabinoids at human CB1 and CB2 receptors. 
5F-MDMB-PICA (EC50 = 0.45 nM) was found to be about 380 times more potent than Δ9-
THC (EC50 = 171 nM) at the CB1 receptor in the assay. Of all the cannabinoids investigated 
in this study, 5F-MDMB-PICA was reported to be the most potent. Regarding human 
metabolism, the product of ester hydrolysis has been shown to be the main phase I 
metabolite (Mogler et al., 2018b). 
Toxicology 
Cases of severe and fatal poisonings involving 5F-MDMB-PICA have been reported in the 
literature (Kleis et al., 2020; Nogee et al., 2019). 
Dependence and abuse potential 
There are no data available in the literature on the potential of 5F-MDMB-PICA to produce 
dependence or on its abuse potential. 
Epidemiology in Germany 
Shortly after 5F-MDMB-PICA was reported to the EMCDDA, 25 herbal blends containing 5F-
MDMB-PICA were seized by police during a raid on a head shop in Germany. During the 
market monitoring of products test-purchased and analysed at the Institute of Forensic 
Medicine, Freiburg (Germany), 5F-MDMB-PICA was one of the most frequently detected 




synthetic cannabinoids from the second half of 2016 onwards. Despite its regulation under 
the German NpSG, which entered into force in November 2016, it was still detected in 
approximately 20 % of all test-purchased products in 2019, but with declining prevalence in 
2020 (it was scheduled under the German Narcotics Act in July 2020). In urine samples 
analysed at the Institute of Forensic Medicine, Freiburg, the first positive samples occurred in 
2016 (making up about 8 % of all positive samples). In 2017 and 2018, the prevalence 
dropped to less than 5 %. In 2019, the prevalence in urine samples sharply increased, with 
more than 45 % of all positive samples testing positive for its metabolites. In 2020, the 
prevalence rose to more than 50 % from January to June and dropped in the second half of 
the year (although it was still more than 20 % in the final quarter of 2020). A similar trend was 
seen for serum samples positive for AMB-FUBINACA (own unpublished data). This might be 
a consequence of the control, for example of 5F-ADB and AMB-FUBINACA, but not 5F-
MDMB-PICA, put in place in August 2018 in China (UNODC, 2018). 
Structurally related synthetic cannabinoids 
Most of the structurally related indole or indazole carboxamide-type synthetic cannabinoids 
showing tert-leucinate linker groups emerged on the European drug market between 2015 
and 2016. The most prominent representatives are 5F-ADB (5F-MDMB-PINACA), MDMB-
CHMICA and MDMB-FUBINACA. 
 
   
 5F-MDMB-PINACA MDMB-CHMICA MDMB-FUBINACA 
Molecular formula C20H28FN3O3 C23H32N2O3 C22H24FN3O3 
Molecular weight 377.4530 g/mol 384.5118 g/mol 397.4427 g/mol 
Monoisotopic mass 377.2115 384.2413 397.1802 
  




Annex 2. Synthetic cannabinoids monitored by the EMCDDA through the EU 
Early Warning System on new psychoactive substances (as of 16 April 2021) 
 










































2 July 2020 














22 June 2020 
CUMYL-CBMINACA 1-(Cyclobutylmethyl)-N-(2-phenylpropan-2-yl)-
1H-indazole-3-carboxamide 




















12 July 2019 
5F-JWH-398 (CL-
2201) 
1-(5-Fluoropentyl)-3-(4-chloro-1-naphthoyl)indole 7 May 2019 
5F-A-P7AICA N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-
pyrrolo[2,3-b]pyridine-3-carboxamide 







9 January 2019 























9 October 2018 
AMB-4en-PICA Methyl 3-methyl-2-[1-(pent-4-en-1-yl)-1H-indole-
3-carboxamido]butanoate 
24 August 2018 
MDMB-4en-PINACA Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-
indazole-3-carboxamido)butanoate 
23 August 2018 
MPhP-2201 Methyl 2‐{[1‐(5‐fluoropentyl)‐1H‐indol‐3‐
yl]formamido}‐3‐phenylpropanoate 
22 August 2018 
A-CHMINACA N-(1-Adamantyl)-1-(cyclohexylmethyl)indazole-3-
carboxamide 
3 July 2018 
MBA-CHMINACA 2-[[1-(Cyclohexylmethyl)indazole-3-
carbonyl]amino]-3-methyl-butanoic acid 
22 June 2018 
DMBA-CHMINACA 2-[[1-(Cyclohexylmethyl)indazole-3-
carbonyl]amino]-3,3-dimethyl-butanoic acid 

















4 July 2017 
5Cl-MDMB-PINACA Methyl 2-[[1-(5-chloropentyl)indazole-3-
carbonyl]amino]-3,3-dimethyl-butanoate 






8 June 2017 
SDB-006 N-phenyl 
analogue 





19 May 2017 
MDMB-PCZCA Methyl 3,3-dimethyl-2-[(9-pentylcarbazole-3-
carbonyl)amino]butanoate 
11 May 2017 
5Cl-AB-PINACA N-(1-Carbamoyl-2-methyl-propyl)-1-(5-
chloropentyl)indazole-3-carboxamide 













































4 March 2016 


















































6 July 2015 
CBL-018 Naphthalen-1-yl 1-pentyl-1H-indole-3-carboxylate 2 July 2015 
5F-EMB-PINACA Ethyl 2-[[1-(5-fluoropentyl)indazole-3-
carbonyl]amino]-3-methyl-butanoate 
17 June 2015 
EMB-FUBINACA Ethyl 2-[[1-[(4-fluorophenyl)methyl]indazole-3-
carbonyl]amino]-3-methyl-butanoate 
17 June 2015 
5C-AKB48 N-(1-Adamantyl)-1-(5-chloropentyl)indazole-3-
carboxamide 
17 June 2015 
5F-PY-PINACA [1-(5-Fluoropentyl)-1H-indazol-3-yl](pyrrolidin-1-
yl)methanone 
17 June 2015 
5F-PY-PICA [1-(5-Fluoropentyl)-1H-indol-3-yl](pyrrolidin-1-
yl)methanone 






12 June 2015 
AMB-CHMINACA Methyl 2-[[1-(cyclohexylmethyl)indazole-3-
carbonyl]amino]-3-methyl-butanoate 
28 May 2015 
MDMB-FUBICA Methyl 2-[[1-[(4-fluorophenyl)methyl]indole-3-
carbonyl]amino]-3,3-dimethyl-butanoate 
4 May 2015 













7 April 2015 
5F-ADB-PINACA N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-1H-indazole-3-carboxamide 
31 March 2015 
SDB-005 Naphthalen-1-yl 1-pentyl-1H-indazole-3-
carboxylate 
31 March 2015 




































































































4 August 2014 
FUB-AKB48 N-(1-Adamantyl)-1-[(4-
fluorophenyl)methyl]indazole-3-carboxamide 
18 July 2014 
MN-18 N-(Naphthalen-1-yl)-1-pentyl-1H-indazole-3-
carboxamide 
9 July 2014 
EG-018 Naphthalen-1-yl(9-pentyl-9H-carbazol-3-
yl)methanone 
20 June 2014 
JWH-071 (1-Ethyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 





18 June 2014 
5F-AMBICA N-(1-Carbamoyl-2-methyl-propyl)-1-(5-
fluoropentyl)indole-3-carboxamide 
29 April 2014 
AB-CHMINACA N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide 






































carboxylic acid 8-quinolinyl ester 
19 December 
2013 






































































5 July 2013 
JTE-907 N-(1,3-Benzodioxol-5-ylmethyl)-2-hydroxy-7-
methoxy-8-pentoxy-quinoline-3-carboxamide 
4 July 2013 
AB-FUBINACA N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-
fluorobenzyl)-1H-indazole-3-carboxamide 




3 June 2013 
AB-PINACA N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-
1H-indazole-3-carboxamide 
21 May 2013 





17 April 2013 










4 April 2013 
JWH-145 1-Naphthyl-(1-pentyl-5-phenyl-pyrrol-3-
yl)methanone 
4 April 2013 
JWH-030 Naphthalen-1-yl(1-pentyl-1H-pyrrol-3-
yl)methanone 








































Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate 20 November 
2012 
















































18 July 2012 
AM-694 methyl 
substituted for iodine 
[1-(5-Fluoropentyl)-1H-indol-3-yl](2-
methylphenyl)methanone 





18 July 2012 
AM-694 ethyl 
substituted for iodine 
(2-Ethylphenyl)[1-(5-fluoropentyl)-1H-indol-3-
yl]methanone 
18 July 2012 











18 July 2012 
AM-6527 1-Pentyl-N-(naphthalen-1-yl)-1H-indole-3-
carboxamide 





13 July 2012 
STS-135 N-(1-Adamantyl)-1-(5-fluoropentyl)indole-3-
carboximidic acid 
26 June 2012 
UR-144 (-2H) [1-(Pent-4-en-1-yl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
14 June 2012 
Apinaca N-(1-Adamantyl)-1-pentyl-1H-indazole-3-
carboxamide 
21 May 2012 
A-796,260 [1-[2-(4-Morpholinyl)ethyl]-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)-methanone 
18 April 2012 
5F-UR-144 (XLR-11) [1-(5-Fluoropentyl)indol-3-yl]-(2,2,3,3-
tetramethylcyclopropyl)methanone 























































5 August 2011 
Org 27759 N-[2-[4-(Dimethylamino)phenyl]ethyl]-3-ethyl-5-
fluoro-1H-indole-2-carboxamide 
5 August 2011 
AM-2233 (2-Iodophenyl){1-[(1-methylpiperidin-2-yl)methyl]-
1H-indol-3-yl}methanone 




5 August 2011 
JWH-307 [5-(2-Fluorophenyl)-1-pentyl-pyrrol-3-yl]-(1-
naphthyl)methanone 
5 August 2011 








20 July 2011 
JWH-387 (4-Bromonaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 
20 July 2011 
RCS-4(C4) (1-Butyl-1H-indol-3-yl)(4-
methoxyphenyl)methanone 
30 June 2011 
MAM-2201 [1-(5-Fluoropentyl)indol-3-yl]-(4-methyl-1-
naphthyl)methanone 





26 May 2011 
AM-1220 [1-[(1-Methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-
1-naphthalenyl-methanone 
25 May 2011 
JWH-007 (2-Methyl-1-pentyl-indol-3-yl)-(1-
naphthyl)methanone 





25 May 2011 
RCS-4 ortho isomer (2-Methoxyphenyl)(1-pentyl-1H-indol-3-
yl)methanone 






17 March 2011 
JWH-182 (1-Pentylindol-3-yl)-(4-propyl-1-
naphthyl)methanone 
1 March 2011 
JWH-018 adamantoyl 
derivative (AB-001) 
1-Adamantyl-(1-pentylindol-3-yl)methanone 22 February 
2011 




Common name IUPAC name Date of formal 
notification 



























CP-47,497 (C8 C2) N/A 17 August 2010 
JWH-015 (2-Methyl-1-propyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
27 July 2010 
JWH-122 (4-Methyl-1-naphthyl)-(1-pentylindol-3-
yl)methanone 
23 July 2010 
AM-694 [1-(5-Fluoropentyl)-1H-indol-3-yl](2-
iodophenyl)methanone 





30 June 2010 








2 June 2010 
RCS-4 (4-Methoxyphenyl)(1-pentyl-1H-indol-3-
yl)methanone 







6 October 2009 
JWH-398 (4-Chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 




22 June 2009 
JWH-073 (1-Butyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
























Common name IUPAC name Date of formal 
notification 
5F-ADBICA N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-1H-indole-3-carboxamide 
N/A 
 
 
